Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 2  1. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS 
1.  TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ........ .........2 
2.  SYNOPSIS ...................................................... .............................................................7  
SCHEDULES OF ASSESSMENTS AND PROCEDURES ....................... ..................................11  
LIST OF ABBREVIATIONS ......................................... ...............................................................18  
3.  INTRODUCTION AND BACKGROUND ...............................................................21  
3.1.  Introduction .................................................. ...............................................................21  
3.2.  Study Drug Background ......................................... ....................................................22  
3.3.  Summary of Findings to Date ................................... ..................................................22  
3.3.1.  Nonclinical Experience ........................................ .......................................................22  
3.3.2.  Clinical Experience ........................................... ..........................................................22  
3.3.3.  Summary of Known and Poten tial Risks of GBT021601 ..........................................23  
3.4.  Study Rationale ...........................................................................................................23  
3.4.1.  Rationale for Study Design .........................................................................................23  
3.4.2.  Rationale for Dose Selection .................................. ....................................................23  
3.4.2.1. Rationale for Single Dose Selection ........................... ................................................23  
3.4.2.2. Rationale for Multiple Dose Selection .......................................................................25  
3.4.2.3. Rationale for Evaluation  of Higher Dose of GBT021601 .......... ................................25  
   
4.  TRIAL OBJECTIVES AND PURPOSE ....................................................................27  
4.1.  Primary Objective .......................................................................................................27  
4.2.  Secondary Objectives .................................................................................................27  
4.3.  Overall Study Design .......................................... ........................................................27  
4.3.1.  Single-dose Period (Part A) ........................................................................................28  
4.3.2.  Multiple Ascending-dose Period (Part B) ....................... ............................................28  
4.3.3.  Extended Treatment Period (Part C) ............................ ...............................................28  
4.4.  Number of Participants ...............................................................................................29  
4.5.  Duration of Study ............................................. ..........................................................29  
4.6.  Definition of Study Completion ................................ .................................................29  
4.7.  End of Study ...............................................................................................................29  
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 3  5.  SELECTION AND WITHDRAW AL OF PARTICIPANTS ...................... ...............30  
5.1.  Participant Inclusion Criteria ................................ ......................................................30  
5.2.  Participant Exclusion Criteria .....................................................................................30  
5.2.1.  Additional Exclusion C riteria (Part C): ....................... ...............................................32  
5.3.  Participant Re -Screening ............................................................................................33  
5.4.  Participant Withdrawal ........................................ .......................................................33  
5.5.  Early Termination of Study .................................... ....................................................33  
5.5.1.  Stopping Rules ............................................................................................................34  
5.6.  Safety Monitoring Committee ................................... .................................................34  
5.7.  Dose Escalation Criteria .............................................................................................35  
6.  TREATMENT OF PARTICIPANTS .........................................................................36  
6.1.  Description of Study Drug ..........................................................................................36  
6.2.  Treatments Administered ....................................... .....................................................36  
6.3.  Method of Assigning Participant s to Treatment Groups ............................................36  
6.4.  Measurements of Treatment Compliance ...................................................................36  
6.5.  Concomitant Medications, Procedur es, Other Restrictions and Req uirements ..........37  
6.5.1.  Concomitant Medications and Procedures ........................ .........................................37  
6.5.2.  Other Restrictions .......................................................................................................37  
6.5.3.  Fertility and Contraceptive Requirements ...................... ............................................37  
6.5.3.1. Female Participants of Childbearing Potential ...........................................................37  
6.5.3.2. Instructions for Male Particip ants Capable of Fathering a Child  ...............................38  
6.5.3.3. Acceptable Forms of C ontraception for Male Participants with Fe male 
Partners Capable of Reproduction ..............................................................................38  
7.  STUDY DRUG MATERIALS AND MANAGEMENT ...........................................39  
7.1.  Study Drug ..................................................................................................................39  
7.2.  Study Drug Packaging and Labeling ..........................................................................39  
7.3.  Study Drug Storage .....................................................................................................39  
7.4.  Blinding of Treatment Assignment .............................. ..............................................39  
7.5.  Administration ................................................ ............................................................39  
7.6.  Study Drug Accountability and Disposal ........................ ...........................................39  
8.  PHARMACOKINETIC AND PHARMA CODYNAMIC ASSESSMENTS ............40  
8.1.  Blood Sample Collection ....................................... .....................................................40  
8.1.1.  Single-dose Period ......................................................................................................40  
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 4  8.1.2.  Multiple Ascending-dose Period ................................ ................................................40  
8.2.  Pharmacokinetic Analysis ..........................................................................................42  
8.3.  Pharmacodynamic Analysis ...................................... ..................................................42  
8.3.1.  Other Pharmacodynamic Assessments ............................. ..........................................42  
9.  ASSESSMENT OF SAFETY .....................................................................................44  
9.1.  Safety Parameters .......................................................................................................44  
9.1.1.  Demographic/Medical History ................................... ................................................44  
9.1.2.  Vital Signs ................................................... ...............................................................44  
9.1.3.  Weight and Height ............................................. .........................................................44  
9.1.4.  Physical Examination .......................................... .......................................................44  
9.1.5.  Electrocardiogram .......................................................................................................44  
9.1.6.  Laboratory Assessments ........................................ .....................................................45  
9.1.6.1. Standard Clinical Lab oratory Assessments ...................... ..........................................45  
9.1.6.2. Other Laboratory Assessments ...................................................................................45  
   
10.  ASSESSMENT OF SAFETY — ADVERSE EVENTS ............................................48  
10.1.  Adverse and Serious Adverse Events ............................ .............................................48  
10.1.1.  Definition of Adverse Events .....................................................................................48  
10.1.2.  Serious Adverse Event ......................................... .......................................................48  
10.2.  Severity .......................................................................................................................49  
10.3.  Relationship to Study Drug ........................................................................................49  
10.4.  Unexpected Adverse Reactions ..................................................................................50  
10.5.  Recording Adverse Events .........................................................................................50  
10.5.1.  General ........................................................................................................................50  
10.5.2.  Diagnosis Versus Signs and Symptoms ........................... ..........................................50  
10.5.3.  Abnormal Laboratory Values .................................... .................................................50  
10.6.  Reporting Adverse Events ...................................... ....................................................51  
10.6.1.  Serious Adverse Events ........................................ ......................................................51  
10.6.2.  Reporting Suspected Unexpected S erious Adverse Reactions and Ur gent 
Safety Issues ...............................................................................................................51  
10.7.  Pregnancy ..................................................... ..............................................................51  
10.8.  Drug-induced Liver Injury ..........................................................................................52  
11.  STATISTICS ..............................................................................................................53  
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 5  11.1.  Sample Size Calculation ....................................... ......................................................53  
11.2.  Analysis Populations ..................................................................................................53  
11.3.  Interim Analysis ..........................................................................................................53  
11.4.  Safety Analysis ............................................... ............................................................53  
11.5.  Pharmacokinetic Analysis ..........................................................................................53  
11.6.  Pharmacodynamic Analysis ...................................... ..................................................53  
11.7.  Pharmacokinetic/Pharmacodynamic Relationships ................. ...................................53  
12.  DIRECT ACCESS TO SOURCE  DATA/DOCUMENTS ........................ .................54  
12.1.  Source Data .................................................................................................................54  
12.2.  Data Collection ...........................................................................................................55  
13.  QUALITY CONTROL AND QUALITY ASSURANCE ......................... ................56  
13.1.  Monitoring ..................................................................................................................56  
13.2.  Quality Control and Quality Assurance ......................... .............................................56  
13.3.  Laboratory Accreditation ...................................... ......................................................56  
14.  ETHICS ........................................................ ..............................................................57  
14.1.  Ethical Conduct of the Study .................................. ....................................................57  
14.2.  Good Clinical Practice ................................................................................................57  
14.3.  Informed Consent .............................................. .........................................................57  
14.4.  Institutional Review Board and Regulatory Approval ...............................................57  
14.5.  Essential Documentation Requirements .....................................................................58  
14.6.  Confidentiality ............................................................................................................58  
14.7.  Regulatory, Ethical, and Legal Obligations .................... ............................................58  
14.8.  Study Documentation and Data Storage .......................... ...........................................58  
15.  DATA HANDLING AND RECORDKEEPING ............................... ........................60  
15.1.  Inspection of Records .................................................................................................60  
15.2.  Retention of Records ..................................................................................................60  
15.3.  Disclosure of Information ...........................................................................................61  
16.  INSURANCE AND FINANCIAL DISCLOSURE ............................ ........................62  
17.  PUBLICATION POLICY ..........................................................................................63  
18.  REFERENCES .................................................... .......................................................64  
   
 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 7  2. SYNOPSIS 
Study Number and Title: 
GBT021601-012: An Intrapatient Single Dose and Multiple Ascendi ng Dose Study to Evaluate the 
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of  GBT021601, a Hemoglobin S 
Polymerization Inhibitor, in Participants with Sickle Cell Dise ase (SCD). 
Study Short Title: 
GBT021601-012 Single Dose and Multiple Ascending Dose in Partic ipants with SCD. 
Estimated Number of Study Centers and Countries or Regions: Up to 3 sites in the United States of America. 
Study Rationale: 
This study will evaluate the pharmacokinetics (PK), safety, tol erability, and pharmacodynamics (PD) 
with a single dose followed by ascending, intrapatient doses of GBT021601, a hemoglobin S (HbS) 
polymerization inhibitor, in participants with SCD. 
Objectives: 
Primary 
 To evaluate the safety and tole rability of a single dose and mu ltiple ascending doses of 
GBT021601 in participants with SCD. 
Secondary 
 To evaluate the PK of a single dose and multiple ascending dose s of GBT021601 in 
participants with SCD. 
 To evaluate the PD properties (e ffect on Hb oxygen equilibrium curves (OEC) as measured 
by % Hb modification and p50) of a single dose and multiple ascending doses of 
GBT021601 in participants with SCD. 
 To confirm the relationship betw een time matched GBT021601 conc entrations and the 
change from baseline or % change  from baseline of clinical meas ures of anemia and 
hemolysis. 
 
  
  
 
 
Study Design: 
This is an open-label, intrapatient, single dose followed by a multiple dose escalation study in at least 
six (6) participants with SCD.  Single-dose Period (Part A) 
After eligibility has been confirme d and the informed consent f orm signed, participants will be 
admitted into the clinical resear ch unit (CRU) on the day prior to study drug administration (Day -1). 
On Day 1 a single oral dose of  GBT021601 will be administered f ollowing an overnight fast of at least 
10 hours and no food will be allowed for at least 4 hours postd ose. A dose of 100 mg is planned but the 
decision regarding the actual study dose will depend on the findings in the single ascending dose 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 9  Number of Participants: 
At least six (6) participants with SCD. Participants in Part A (single dose) will continue to Part B 
(multiple ascending-dose). As of Protocol Amendment 5, all elig ible participants will proceed with the 
extended treatment period (Part C). 
Participant Selection Criteria: Participants with SCD ages 18 to 60 years, inclusive. 
Test Product, Dose, Route of Administration, and Duration of Tr eatment: 
Single-dose Period (Part A) 
 GBT021601 will be provided as a single dose, orally administere d, 100 mg tablet. 
Multiple Ascending-dose Period (Part B) and Extended Treatment Period (Part C) 
 GBT021601 will be provided as orally administered multiple dose tablets and/or capsules for 
approximately 6 to 8 weeks (Part B) and for the approximately 6-week Extended Treatment Period (Part C).  
 Loading and maintenance doses a nd frequency will be determined based on PK results from 
GBT021601-011 and on PK and /or hemoximetry results from Part A . Dose escalations will 
not exceed 2-fold the previous dose. For the Extended Treatment  Period, the loading dose will 
be 300 mg, twice daily, for 4 days followed by a once daily mai ntenance dose of 150 mg. 
Criteria for Evaluation: 
Safety:  Participant safety and tolerability will be monitored during th e study using standard measures, 
including physical examination, v ital signs, 12-lead electrocardiogram, safety laboratory assessments 
(hematology measurements, chemist ry measurements [including mea sures of hemolysis]), urinalysis, 
concomitant medication usage a nd adverse event monitoring. 
Pharmacokinetics: Plasma and whole blood concentr ations of GBT021601 will be determined using validated assay 
methods. Red blood cell (RBC) concentrations will be calculated . The following whole blood, plasma, 
and RBC PK parameters of GBT021601 will be calculated, if appropriate. See below for PK 
parameters to be collected during each phase. 
Single-dose Period (Part A): Maximum plasma/whole blood concent ration (C
max), time of maximum 
serum concentration (t max), area under the concentration vs time curve from time zero to  24 hours 
(AUC 0-24), area under the concentration vs time curve from zero to last  quantifiable concentration 
(AUC 0-t), area under the concentration vs time curve from time zero extrapolated to infinity (AUC 0-∞), 
apparent clearance (CL/F), appare nt volume of distribution duri ng the terminal phase (Vz/F), half-life 
(t1/2) and % Hb occupancy. 
Multiple Dose (Part B and Part C): Plasma/whole blood C max, plasma/whole blood C min, plasma/whole 
blood AUC at steady-state, half-life (t ½) and % Hb occupancy. 
Pharmacodynamics (Parts A, B, and C): 
Hemoximetry (the partial pressure of oxygen at which the hemogl obin protein is 20% and 50% 
saturated [p20 and p50, respectively]), RBC deformability, and serum erythropoietin will be measured. 
The relationship between time ma tched GBT021601 concentrations and the change from baseline or % 
change from baseline of clinical measures of anemia and hemolysis will be evaluated. 
 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 10  Planned Sample Size: 
Due to the exploratory nature of this study, no formal power or  sample size calculations were used to 
determine cohort size. A sample size of at least 6 participants  with SCD are expected to provide 
adequate characterization of PK and safety for both the Single-dose Period and the Multiple 
Ascending-dose Period. 
Statistical Analysis: 
Adverse events will be coded to system-organ class and preferre d term using the Medical Dictionary 
for Regulatory Activities (MedDRA) and summarized. Vital signs and laboratory safety assessments 
will be presented with identification of clinically significant  values and those outside of normal range. 
Electrocardiogram data 
will be presented with any clinically relevant abnormal finding s or changes highlighted. The PK and 
PD parameters will be listed a nd summarized using appropriate descriptive statistics. 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 11  SCHEDULES OF ASSESSMENTS AND PROCEDURES 
Table 1: Schedule of Assessments  for Single-dose Period (Part A ) 
 Screen Confinement Outpatient 
Study Day -30 to -2 -1 1 2 3 4 7 14 21 28 42 
I n f o r m e d  c o n s e n t  X            
Eligibility assessment X X          
Medical historya X            
Physical examinationb X X    X      
H e i g h t  X            
Weight X X    X  X  X  X  X  X  
Vital signsc X X X X X X X X X X X 
12-lead ECG (triple tracing)d X X X X X X  X  X  
Study drug administration    X         
Serology (hepatitis A, B, C) HIV, SARS-CoV-2 X           
Alcohol (breath or blood) and urine drugs of abuse 
screen X  X           
Hematology, Serum chemistry, and Lipid Panele X  X   X   X   X   X   
a P T T ,  I N R ,  P T  X            
Serum erythropoietin  X X   X  X  X  
S C D  d o c u m e n t a t i o n  o r  H e m o g l o b i n  E l e c t r o p h o r e s i s  X            
eGFRf X  X           
U r i n a l y s i s  X  X     X       
Pregnancy test (women only)g X  X       X   X   
F S H  ( p o s t m e n o p a u s a l  w o m e n  o n l y )  X            
Pharmacokinetic assessment (whole blood and plasma)   X
 X X X X X X X X 
Hemoximetry   X X  X X  X  X 
RBC deformability, dense cellsh   X          
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 12   Screen Confinement Outpatient 
Study Day -30 to -2 -1 1 2 3 4 7 14 21 28 42 
Concomitant medication X X X X X X X X X X X 
A d v e r s e  e v e n t s  X  X  X  X  X  X  X  X  X  X  X  
Abbreviations: aPTT, activated p artial thromboplastin time; CoV , coronavirus; ECG, el ectrocardiogram; eGFR, estimated glomerul ar filtration rate; 
EOS, end of study; ET , early termination; FSH, follicle-stimula ting hormone; HIV, human immunodeficiency virus; INR, Internati onal Normalized Ratio; 
PCR, polymerase chain reaction; P T, prothrombin time; RBC, red blood cell; SARs, severe acute re spiratory syndrome; SCD, sickl e cell disease. 
a History update, if any, will be obtained. 
b A full physical examination should be conducted at Screening. All subsequent physical examinations should be signs and symptoms driven. 
c Vital Signs include blood pressu re, heart rate, respiration ra te, body temperature while the participant is in a supine posit ion. See Table 2.  
d 12-Lead ECG on Day 1 should be performed within 30 minutes pri or to dose, and 4 and 8  hours after dosing , then in the morning of each day o f confinement 
and at any time at other clinic visits. See Table 2.  
e The Lipid Panel is done at the Screening Visit only. 
f The eGFR will be calculated at S creening and confirmed on Day -1 using the Cockcroft-Gault formula. 
g A serum pregnancy test will be c onducted at Screening and ET a nd urine pregnancy test at all other visits. A serum pregnancy test will also be conducted when 
a positive urinary pregnancy te st occurs for confirmation. 
h RBC deformability and dense cells will be tested on Day 1 predose and 12 hours postdose. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 13  Table 2: Schedule of Select Stu dy Procedures (First 48 hours) 
Procedure  Sampling Timepoint 
Pre 
dose Postdose (hours) 
0.25 hr 0.5 hr 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 
(Day 2) 36 hr 48 hr 
(Day 3) 
HR and BPa, b X     X X X X X X  X 
RR and Body Temperaturea, b X          X   X  
12-lead safety ECGsb, c X    X   X   x   X   X  
PK Samplingd X  X X  X X X X X X X X X 
Abbreviations: BP, blood pressure; ECG, electrocardiogram; HR, heart rate; PK, pharmacokinetic ; RR, respiratory rate; SAD, sin gle ascending dose. 
Note: For procedures scheduled t o be performed at the same time , priority is to be given to collection of the PK samples at th e designated time. 
ECGs, followed by vital signs, are  to be taken before PK sampling, unless PK samples will be lat e as a result. If times are de layed due to technical difficulties, 
this will be noted, but not cons idered a protocol deviation. 
a HR, BP, RR, and body temperature will be measured after a part icipant has rested for at leas t 5 minutes in the supine positio n.  
b Window for collection: up to 3 hours predose, ± 15 minutes up to 12 hours post, ± 30 minutes if ≥ 24 hours postdose. 
c ECGs (12-lead) will be collected  in triplicate within 5 minute s after a participant has rested  at least 5 minutes in the supi ne position. Pre-dose ECGs and vital 
signs on Day 1 may be performed within 3 hours prior to dosing.  
d Predose blood PK sample to be collected within 60 minutes prio r to dosing. Postdose collection windows are: 0.25, 0.5 and 1 h our ± 2 mins, 2 to 24 hours 
± 5 mins, 36 and 48 hours ± 10 mins. 
 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 14  Table 3: Schedule of Assessments  for Multiple Ascending-dose Period (Part B)  
Study Week  Week 8  
(Day 56  
+ 4 
weeks)a Week 9  
(Day 63  
± 3 days) Week 10  
(Day 70  
± 3 days) Week 11  
(Day 77  
+ 3 days  Week 12  
(Day 84  
± 3 days) Week 13  
(Day 91  
±3 days) 
 Week 14  
(Day 98)  
± 3 days) Week 15 
(Day 105 ) 
±3 days  
 Week 16 
(Day 112) 
EOT 
 Every 
4 weeks 
through 
EOB 
± 7 days Day 218  
(EOB/ET) 
P h y s i c a l  e x a m i n a t i o n  X      X    X   X  
H e i g h t             
W e i g h t  X   X          
Vital signsc X  X  X  X  X  X  X  X  X   X  
12-lead ECG 
(triple tracing)d X      X    X   X  
Study drug administration X
e X  X  X  X  Xf X  X  X    
Dispense patient diary
g X X X X X X X X    
Collect patient diaryg
g  X  X  X  X  X  X  X  X    
Hematology and serum chemistry X  X  X X  X X X X 
Blood smearh X         X   X  
Serum erythropoietin X     X X  X   
eGFRi X     X     X  
Urinalysis X     X     X  
Pregnancy test (women only)
j X     X      
Pharmacokinetic assessment (whole blood and plasma)
k X X X X X X X X X X X 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 15  Study Week  Week 8  
(Day 56  
+ 4 
weeks)a Week 9  
(Day 63  
± 3 days) Week 10  
(Day 70  
± 3 days) Week 11  
(Day 77  
+ 3 days  Week 12  
(Day 84  
± 3 days) Week 13  
(Day 91  
±3 days) 
 Week 14  
(Day 98)  
± 3 days) Week 15 
(Day 105 ) 
±3 days  
 Week 16 
(Day 112) 
EOT 
 Every 
4 weeks 
through 
EOB 
± 7 days Day 218  
(EOB/ET) 
Hemoximetryk X X X   X  X X  X 
RBC deformability, 
dense cells (if feasible)
k X X X   X  X X  X 
Concomitant medications X X X X X X X  X  X 
A d v e r s e  e v e n t s  X  X  X  X  X  X  X   X   X  
Clinic visit X X X X X X X  X  X 
Abbreviations: ECG, electrocardiogram; eGFR, estimated glomerul ar filtration rate; EOB, end of Part B; ET, early termination; RBC, red blood cell. 
Note: For procedures scheduled t o be performed at the same time , priority is to be given to collection of the PK samples at th e designated time. 
ECGs, followed by vital signs, are  to be taken before PK sampling unless PK samples will be late as a result 
a Week 8 (Day 56) is the first v isit in the Multiple-Ascending-d ose Period.  
b The Day 218 Visit will occur approximately 5 half-lives after the dose at Week 16. 
c HR, BP, RR, and body temperature will be measured after a part icipant has rested for at leas t 5 minutes in the supine positio n. Assessment of vital signs may be 
performed up to 3 hours predose. 
d 12-Lead ECG should be performed within 30 minutes prior to dose  and will be collected in tripli cate within 5 minutes after a p articipant has rested at least 
5 minutes in the supine position. 
e Study drug will be administered as a loading dose of TBD mg an d a maintenance dose of TBD mg every TBD (Dose 1) beginning at the Week 8 (Day 56) 
Visit. Participants will receive m aintenance Dos e 1 through Wee k 10. At the Week 8 Visit, the p articipant will remain in the c linic for 4 hours postdose for 
vitals, 12-lead ECG and AE assessment. 
f Study drug will be administered as a loading dose of TBD mg an d a maintenance dose of TBD mg every TBD (Dose 2) beginning at the Week 13 (Day 91) 
Visit. Participants will receive m aintenance Dos e 2 through Wee k 16. At the Week 13 Visit, the  participant will remain in the clinic for 4 hours postdose for 
vitals, 12-lead ECG and AE assessment 
g Site to dispense a new diary and  collect the previous diary fr om the patient, when applicable. Diary to be collected only dur ing the maintenance dosing when 
the participant is self-administering study drug at home. Parti cipants should be instructed to complete the diary each week an d return it at the next visit for site 
review. 
h A blood smear is to be performe d before the Multiple Ascending  Dosing Period Day 56 and Day 112 visits. 
i The eGFR will be calculated usin g the Cockcroft-Gault formula.  
j A urine pregnancy test will be conducted. A serum pregnancy test will also be conducted when a positive urinary pregnancy tes t occurs for confirmation. 
k Samples for PK will be collected : predose, 0.25 to 1 hours pos tdose and 2 to 4 hours postdose. Sample collection times for he moximetry and RBC 
deformability should be aligned with the predose PK sample and the 2 to 4 hour postdose PK samp le. No 0.25 to 1 hour postdose sample shall be collected for 
hemoximetry or RBC deformability. T he predose blood sample for PK and PD assessments should be c ollected within 30 minutes pri or to dosing. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 16  Table 4: Schedule of Assessments f or Extended Treatment Period (Part C) 
Study Day/Week   Part C 
Screening  
Visit  
(Day -28 to 
Day -1) 
 Part C 
 Day 1 Part C  
Week 2  
(Day 14  
± 3 days) Part C  
Week 4  
(Day 28   
± 3 days) 
         Part C  
Week 6 
(Day 42)  
± 3 days)   
EOET Part C  
Week 10 
(Day 70 ± 3 
days)  Part C  
Week 14 
(Day 98 ± 3 
days)  Final Visit  
(EOS/  
Informed Consent X        
Eligibility confirmationa X         
Physical examination X    X  X X 
Weight X X   X  X X 
Vital signsb X  X  X  X  X  X  X  X  
12-lead ECG (triple tracing)c X X X X X  X X 
Study drug administrationd  X X X X    
Dispense participant diarye  X X X     
Collect participant diarye   X  X  X     
         
         
Hematology and serum 
chemistry X X X X X X X X 
Serum erythropoietin X X   X  X X 
eGFRf X X   X  X X 
Urinalysis X X   X  X X 
Pregnancy test (women only)
g X X   X  X X 
Pharmacokinetic assessment (whole blood and plasma)
h  X  X  X  X  X  X  X  
Hemoximetryh  X  X X  X X 
CCI
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 18  LIST OF ABBREVIATIONS 
The following abbreviations and specialist terms are used in th is study protocol. 
Abbreviation or 
Specialist Term Explanation 
ADLs Activities of daily living 
AE Adverse event 
ALT Alanine aminotransferase 
aPTT Activated partial thromboplastin time 
AST Aspartate aminotransferase 
AUC 0-24 Area under the concentration vs  time curve from time zero to 24 hours 
AUC 0-t Area under the concentration vs time curve from zero to last quantifiable concentration 
AUC 0-∞ Area under the concentration vs  time curve from time zero extrapolated to infinity 
BP Blood pressure 
BPM Beats per minute 
  
CL/F Apparent clearance 
Cmax Maximum plasma/whole blood concentration 
Cmin Minimum plasma/whole blood concentration 
  
CoV Coronavirus 
COVID-19 Coronavirus disease 2019 
CRO Contract research organization 
CRU Clinical research unit 
CYP Cytochrome P450 
°C Degrees Celsius 
  
DILI Drug-induced liver injury 
ECG Electrocardiogram 
eCRF Electronic case report form 
eGFR Estimated glomerular filtration rate 
EOS End of Study 
EOT End of Treatment 
EPO Erythropoietin 
ET Early Termination 
FDA (United States) Food and Drug Administration 
  
CCI
CCI
CCI
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 19  Abbreviation or 
Specialist Term Explanation 
FIH First-in-human 
FSH Follicle-stimulating hormone 
GBT Global Blood Therapeutics, Inc. 
GCP Good Clinical Practice 
Hb Hemoglobin 
Hb-O 2 Hemoglobin-oxygen 
HbS Sickle hemoglobin 
HbSB Double heterozygote for HbS and b-0 thalassemia 
HbSS Homozygous for sickle cell allele 
HIV Human immunodeficiency virus 
HR Heart rate 
HU Hydroxyurea 
IgM Immunoglobulin M 
IB Investigator’s brochure 
ICF Informed consent form 
ICH International Conference on Harmonisation 
INR International Normalized Ratio 
IRB Institutional Review Board 
MedDRA Medical Dictionary for Regulatory Activities 
NCI CTCAE National Cancer Institute Common Terminology Criteria  for Adverse Events 
NOAEL No-observed-adverse-effect level 
  
  
OxyHb Oxy-hemoglobin 
PD Pharmacodynamics 
PK Pharmacokinetics 
PT Prothrombin time 
p20 Hemoglobin protein is 20% saturated 
p50 Hemoglobin protein is 50% saturated 
RBC Red blood cell 
RR Respiratory rate 
SAD Single ascending dose 
SAE Serious adverse event 
SARS Severe acute respiratory syndrome 
SCD Sickle cell disease 
SMC Safety Monitoring Committee 
CCI
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 20  Abbreviation or 
Specialist Term Explanation 
tmax Time of maximum serum concentration 
t½ Half-life 
ULN Upper limit of normal 
US United States 
Vz/F Apparent volume of distribution during the terminal phase 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 21  3. INTRODUCTION AND BACKGROUND 
3.1. Introduction 
Global Blood Therapeutics, Inc . (GBT; the Sponsor) intends to d evelop GBT021601, a sickle 
hemoglobin (HbS) polymerization inhibitor for the treatment of sickle cell disease (SCD). 
Sickle cell disease is an inherited disorder caused by a point mutation in the β-globin gene 
leading to formation of HbS. A  primary and obligatory event in the molecular pathogenesis of 
SCD is the polymerization of intracellular HbS following deoxyg enation in the microvasculature. 
HbS polymerization leads to decreased red blood cells (RBC) def ormability, morphologic 
sickling of RBCs, decreased RBC survival, and microvascular obs truction ( Bunn, 1997). 
Clinically, SCD is a devastati ng and debilitating disease marked by the pathophysiologic features 
of hemolytic anemia, vaso-occlus ion, and progressive end-organ damage. Despite current 
standards of care, including hydroxyurea (HU), blood transfusion, and supportive care with 
analgesia, patients with SCD c ontinue to suffer serious morbidi ty and premature mortality. 
A drug that inhibits HbS polymer ization in all RBCs has the pot ential to provide superior 
efficacy to available treatments. GBT021601 is an HbS polymeriz ation inhibitor being developed 
by GBT for the treatment of SCD . GBT021601 increases hemoglobin -oxygen (Hb-O 2) affinity 
and stabilizes hemoglobin (Hb) in the oxy-hemoglobin (oxyHb) st ate thereby inhibiting 
polymerization of HbS in RBCs. B y addressing this underlying mechanism of SCD, GBT021601 
has the potential to be a dis ease-modifying therapy, leading to  improved anemia, reduced 
hemolysis and the potential to reduce the end-organ damage resu lting from chronic hemolytic 
anemia. Proof of concept for this  Hb modification approach has been provided with voxelotor, 
an orally administered small molecule inhibitor of HbS polymeri zation. 
Voxelotor is an allosteric modifier of Hb-O2 affinity and follo wing binding to Hb, stabilizes the 
oxyhemoglobin state ( Metcalf, 2017; Oksenberg 2016 ), thereby inhibiting polymerization of 
HbS in RBCs and in patients with SCD .  
Data from the Phase 3 study of voxelotor in patients with SCD showed a dose-dependent 
improvement in hemolytic anemia, with an increase in Hb and con comitant decrease in clinical 
measures of hemolysis (including indirect bilirubin, reticulocy tes, and lactate dehydrogenase) 
(Vichinsky, 2019 ).  
The % Hb occupancy approximates the percentage of high-affinity  anti-polymerizing oxyHb 
molecules per RBC and is calculat ed as a percentage of the mola r ratio of drug concentration in 
RBCs to the estimated Hb concentration (5000 μM) in RBCs ( Howard, 2019; 
Hutchaleelaha, 2019 ). 
Clinical studies with voxelotor  in patients with SCD showed tha t daily doses of 1500 mg 
(the FDA-approved dose), which achieved a mean Hb occupancy of ~27%, was well tolerated 
and resulted in a clinically m eaningful increase in Hb by > 1 g /dL in > 50% patients with 
concurrent reductions in clinical measures of hemolysis ( Vichinsky, 2019 ). Additionally, the 
highest Hb occupancy achieved in that study with 1500 mg was 45%. In SCD mice treated with GBT021601, a Hb occupancy of ~6% r esulted in a > 1 g/dL increase in Hb concentration in all 
animals. Moreover, at a GBT021601 Hb occupancy of ~29% (similar  to the mean achieved by 
the 1500 mg dose of voxelotor in S CD patients), GBT021601 caused a sustained and almost 
complete elimination of circula ting sickled RBCs, reduced retic ulocyte counts by > 50%, 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 22  increased RBC half-life by 6.1 days, and normalized Hb with a 6 .7 g/dL increase from baseline 
in SCD mice. These data indicate  that at similar Hb occupancies , GBT021601 is expected to be 
more potent than voxelotor in patients with SCD. 
Voxelotor was recently approve d by the United States (US) Food and Drug Administration 
(FDA), under the tradename OXBRYTA®, for the treatment of SCD  in adults and pediatric 
patients 12 years of age and older. 
As stated above, GBT021601 shares the same mechanism of action as voxelotor and thus is 
designed to optimize the potential  for clinical benefit derived  from stabilizing oxyHb.  
Erythropoiesis increases in res ponse to tissue hypoxia, and thi s increase is mediated by tissue 
sensing of hypoxia resulting in an i ncrease in erythropoietin p roduction, which in turn causes an 
increase in reticulocyte production. Because increased erythrop oiesis is the compensatory 
response for decreased tissue oxygen extraction, treatment effe cts on these markers were 
assessed in the Phase 3 voxeloto r study. No evidence of a compe nsatory erythropoietic response 
was seen with voxelotor at 900 m g and 1500 mg: erythropoietin d id not increase and 
reticulocytes decreased. The safety related to pharmaco logy of GBT021601 is also support ed by the safety findings for 
voxelotor, which was found to be w ell tolerated without demonst rated safety concerns in studies 
on both healthy participants  and patients with SCD ( Hutchaleelaha, 2019 ; Vichinsky, 2019 ). 
3.2. Study Drug Background 
GBT021601 increases Hb-O 2 affinity and stabilizes Hb in the oxyHb state thereby inhibiti ng 
polymerization of HbS in RBCs. In preclinical animal studies, G BT021601 partitioned 
preferentially to the RBC compar tment with a mean blood/plasma ratio of 48–122:1. 
Thus, similar to voxelotor, GBT 021601 is expected to partition preferentially into RBCs, 
where it specifically binds t o Hb, and therefore minimizes plas ma exposures. 
3.3. Summary of Findings to Date 
3.3.1. Nonclinical Experience 
Nonclinical studies have been c onducted to characterize GBT0216 01, including primary and 
secondary pharmacodynamics (PD), safety, pharmacology, pharmaco kinetics (PK), and 
toxicology. The results from these studies support planned clinical studies with GBT021601 and 
are described in detail in the GBT021601 Investigator's Brochure . 
3.3.2. Clinical Experience 
A first-in-human (FIH) single ascending and multiple ascending dose (SAD/MAD) study in 
healthy participants (Stu dy GBT021601-011) is ongoing. Safety a nd PK data on single doses 
from 50 mg to 2200 mg in healthy parti cipants has demonstrated that GBT021601 is well 
tolerated with a linear dose-dep endent increase in percent Hb o ccupancy. Safety and PK 
assessments for multi-day loading doses and daily maintenance d oses of 15, 25, and 50 mg for 
14 days has been completed in three cohorts of the MAD. 
For the current Study GBT021601-012, in Part A, six adults with SCD have received a single 100 mg dose of GBT021601, and the dose  has been well tolerated.  After an 8-week washout, 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 24  GBT021601 and correlated with rever sible microscopic changes of  increased hematopoiesis in 
the bone marrow (rats and monkeys ) and spleen (rats). The no-observed-adverse-effect level 
(NOAEL) was 30 mg/kg/day in cyno molgus monkeys and 50 mg/kg/day  in rats following oral 
administration of GBT021601 for 13 weeks ( Table 5 ). 
 
Table 5: Thirteen-Week Oral Toxicity Studies in Rats and Cynomo lgus Monkeys: 
Whole Blood and Plasma Exposures  and Hemoglobin Occupancies Achieved 
at the No-Observed-Adverse-Effect Levels 
Species Day 91: Mean Exposures to GBT021601a 
GBT021601 
NOAEL 
(mg/kg/day) % Hb 
Occupancyb Cmax (µg/mL) AUC 0-t (µg•h/mL) 
Whole 
Blood Plasma Whole Blood Plasma 
Rat 832 33.2 15,750 482 50 60 
Cynomolgus 
monkey 902 23.3 18,600 290 30 83 
Abbreviations: AUC 0-t, area under the concentration-time curve from the start of dose administration to the time at 
which the last quantifiable co ncentration was observed; C max, maximum blood or plasma concentration; 
NOAEL, no-observed-adverse-effect level.  
a Mean of males and females. 
b Estimated by comparing the molar ratio of GBT021601 to hemoglo bin in erythrocytes. 
 In rats, while pharmacologically m ediated increased erythropoiesis was observed at this 60% Hb 
occupancy (and in turn, led to t he designation of 50 mg/kg/day as the NOAEL), these effects are 
monitorable, reversible, and wer e not associated with adverse f indings. Additionally, in a post-
hoc analysis of the pivotal HOPE study, 8 of 81 participants (9 .9%) taking 1500 mg of voxelotor 
daily exceeded 50% Hb occupancy during treatment (GBT data on f ile). Therefore, for these 
reasons, attaining 60% occupancy in a clinical study does not r aise specific safety concerns.  
A dose of 100 mg GBT021601 w as estimated using: 
1. A human equivalent dose of 8 mg /kg/day, derived using the 28-da y rat NOAEL of 
50 mg/kg/day and a body surface ar ea conversion factor of 6.2 ( Table 5 ); 
2. A human body weight of 60 kg; 
3. A safety factor of 5. 
This estimation method is consiste nt with that described in the  United States Food and Drug 
Administration Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial 
Clinical Trials for Therapeutics in Adult Healthy Volunteers  (FDA, 2005). 
For the initial clinical evalu ation in participants with SCD, t he recommended starting dose of 
100 mg GBT021601 will be administered as a single dose. This 2- fold higher starting dose, 
derived using a safety factor of 5 f or participants relative to  that (50 mg using a safety factor of 
10) for healthy participants, is  based on risk-benefit consider ations. Furthermore, key 
GBT021601-related effects in the 28 -day oral studies in rats an d monkeys were consistent with 
exaggerated pharmacological eff ects at high Hb occupancies and were generally reversible, 
indicating a low risk to parti cipants at a dose of 100 mg. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 25  3.4.2.2. Rationale for Multiple Dose Selection 
The starting multiple ascending dose is predicted to achieve a Cmax at steady-state no higher than 
2-fold the C max already achieved and well tolera ted following a single ascendi ng dose or multiple 
ascending dose in healthy part icipants (Study GBT021601-011). T he starting multiple ascending 
dose is also predicted to achie ve ~ 20% to 30% Hb occupancy, a level of Hb 
occupancy/modification which has been well tole rated with voxel otor ( Hutchaleelaha, 2019  and 
Vichinsky, 2019 ). If needed, dose escalation wi ll proceed at up to 2-fold unti l > 30% 
occupancy/modification (40% Hb oc cupancy has been well tolerate d without tissue hypoxia in 
healthy participants with voxelotor [ Hutchaleelaha, 2019 ]) has been reached and by less than 
1.3-fold, thereafter.  
The doses and frequency for the multiple ascending dose period of this study will be determined 
based on the results from the FIH Study GBT021601-011 in health y participants and the single-
dose, Day 42 PK and hemoximetry ana lysis in participants with S CD in this study. At the time of 
the first administration of GB T021601 to participants with SCD,  safety data from the first 5 
cohorts (50, 100, 200, 400, and 800 mg) and PK data from the first 3 cohorts from the SAD FIH 
Study GBT021601 will be available. A Safety Monitoring Committe e (SMC, Section 7.6) will 
convene to review the safety, tolerability, and PK data when a minimum of 4 participants with 
SCD who have received a single dose of GBT021601 have reached W eek 6 (Day 42). If the 
SMC agrees to initiate the intrapatient multiple-dose portion of the study, participants will 
receive a maintenance dose (possibly preceded by a loading dose ) at Week 8 (+ 4 weeks).  
The maintenance dose will be administered for the following 9 w eeks (Week 8 to Week 16). 
After the first multiple dose period (Week 8 through Week 10), if the % Hb occupancy is higher 
than 30%, the participant may rem ain on the same maintenance do se or have a dose increase that 
maintains the % Hb occupa ncy/modification at > 30%.  
If the % Hb occupancy is less tha n 30%, the participant will do se escalate at Week 13. 
At Week 13, eligible part icipants will be dose escalated to rec eive a maintenance dose 
(possibly preceded by a loading dose) based on a predicted targ et of > 30% Hb occupancy as 
determined by the PK results of GBT021601-011 and Day 42 PK and /or hemoximetry from the 
Single-dose Period.  
At the proposed starting dose of 100 mg in SCD participants and  subsequent, intrapatient 
multiple dose escalation, there may be sufficient Hb occupancie s (after multiple dosing) to 
provide potentially beneficial pharmacological effects.  
3.4.2.3. Rationale for Evaluation of Higher Dose of GBT021601 
As of Protocol Amendment 5, aft er a total of 8 weeks of treatme nt, all participants in this study 
demonstrated improvements in h ematologic parameters, including reticulocytes and absolute 
reticulocytes, lactate dehydrogenase, and indirect bilirubin (Brown, 2021). Preliminary findings 
indicate a dose-related mean increase from about 15% to 32% in Hb occupancy after dosing with 
50 mg daily and 100 mg daily respect ively. Preliminary clinical  safety data show that 
GBT021601 has been well tolerate d with no significant treatment -related safety findings 
reported. An extended treatment period evaluating a dose escala tion to 150 mg once daily for at 
least 6 weeks preceded by a loading dose of 300 mg, given twice  daily over 4 days (the loading 
dose is being adm
inistered twice  daily to minimize the potentia l for any gastrointestinal effect 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 29  4.4. Number of Participants 
At least 6 participants will participate in both the Single-dos e Period and the intrapatient 
Multiple Ascending-dose Period. As of Protocol Amendment 5, all eligible participants will 
proceed with the extended treatment period. 
4.5. Duration of Study 
The maximum duration of the st udy is dependent on the half-life  of GBT021601. At a minimum, 
study duration will include a 28-day Screening period, an 8-wee k Single-dose Period, and a 
6-week Multiple Ascending-dose Period for a total of 18 weeks. This will be followed by an 
EOS Visit 5 half-lives after t he final dose of GBT021601. It is  anticipated that the EOS will not 
exceed 120 days after the final dose. As of Protocol Amendment 5, the maximum duration of the 
study will be approximately 53 weeks , which includes the approx imately 6-week Extended 
Treatment Period, and an 8-week follow up. 
4.6. Definition of Study Completion 
The EOB Visit will occur after completion of the Multiple Ascen ding-dose Periods as presented 
in Table 3  and the EOS Visit will occur af ter completion of the Extended Treatment Period as 
presented in Table 4 . 
Participants who terminate from the study early will have Early Termination (ET) 
Visit procedures performed at th e time of discontinuation. Part icipants with ongoi ng clinically 
significant clinical or laboratory findings will be followed un til the finding is resolved or 
medically stable; reasonable attempts will be made to follow-up  with participants. All serious 
and nonserious adverse events (AE s) must be followed until they  are resolved or stabilized, 
or until reasonable attempts to determine resolution of the eve nt are exhausted. The Investigator 
should use his/her discretion in o rdering additional tests as n ecessary to monitor the resolution of 
such events. Participation in the study will end once all study  assessments and visits have been 
completed. 
4.7. End of Study 
The EOS is defined as the date w hen the last participant has co mpleted all study procedures up to 
and including EOS or ET vi sits, as specified in Table 4 .  
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 30  5. SELECTION AND WITHDRAW AL OF PARTICIPANTS 
5.1. Participant Inclusion Criteria 
Participants must meet all inc lusion criteria to be eligible fo r study participation. 
1. Male or female with SCD. 
2. Documentation of SCD genotype homozygous for sickle cell allele  (HbSS) or double 
heterozygote for HbS and β-0 thalassemia (HbSB). 
3. Age 18 to ≤ 60 years, inclusive. 
4. Hb ≥ 5.5 and ≤ 10.5 g/dL during Screening and considered stable  and close to Baseline 
by the Investigator. 
5. For participants taking HU, the  dose in mg/kg must be stable for at least 90 days prior to 
signing the informed consent fo rm (ICF) and with no anticipated  need for dose 
adjustments during the study in t he opinion of the Investigator . 
6. Female participants of child-bearing potential, must agree to use highly effective methods 
of contraception or practice abs tinence from study start to 165  days after the last dose of 
study drug. Males who are not surgi cally sterile with partners of childbearing potential 
must agree to use a highly eff ective method of birth control du ring the study and for 
165 days after the last dose  of study drug. A highly effective method of contraception is 
defined as one that results in a  low documented failure rate wh en used consistently and 
correctly such as: condom plus use of an intrauterine device; intrauterine system or hormonal method of contraception (oral, injected, implanted, or transdermal) for their 
female partner; or sexual abstinence. In addition, males who ar e not surgically sterile with 
a partner who is pregnant must agree to condom use or maintain sexual abstinence during 
the study and for 165 days after t he last dose of study drug.  
7. Males must agree to not donate s perm from stud y start through 1 65 days after the final dose. 
8. Participant has provided documented informed consent. 
5.2. Participant Exclusion Criteria 
Participants meeting any of the following exclusion criteria wi ll not be eligible for study 
enrollment: 
1. More than 10 vaso-occlusive cri ses within 12 months of Screening that required a 
telemedicine, hospital, emergency room, or clinic visit. 
2. Female participant who is breastfeeding or pregnant. 
3. Receiving regularly scheduled RBC transfusion therapy (also ter med chronic, 
prophylactic, or preventive trans fusion) or have received an RB C transfusion for any 
reason within 60 days of signing the  ICF or at any time during the Screening period. 
4. Hospitalized for sickle cell cris is or other vaso-occlusive eve nt within 14 days of signing 
the ICF or within 28 day s prior to the start of study treatment (ie, participants with a 
vaso-occlusive event must wait at least 14 days before signing an ICF and Screening 
period must be at least 14 days  before the start of study treat ment). 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 31  5. Screening laboratory test of ala nine aminotransferase (ALT) > 4  × upper limit of normal 
(ULN). 
6. Acute illness or clinically si gnificant bacterial, fungal, parasitic, or viral infection which 
requires therapy, including acute  bacterial infection requiring antibiotics within 14 days 
prior to the start of st udy drug administration. 
7. Participants with positive Screen ing tests for hepatitis (A, B, or C) or human 
immunodeficiency virus (HIV)  or who are known to have active hepatitis infection or to 
be HIV positive or hepatitis C antibody positive. 
8. Participants with symptomatic c oronavirus disease 2019 (COVID-19) infection, 
temporary exclusion. 
9. Estimated glomerular filtrati on rate (eGFR) < 50 mL/min/1.73 m2 at the Screening Visit, 
calculated by the central laboratory, or is on c hronic dialysis . 
10. History of malignancy within the past 2 years prior to treatmen t Day 1 requiring 
chemotherapy and/or radiation (with the exception of local therapy for non-melanoma 
skin malignancy). 
11. History of unstable or deteriorating cardiac or pulmonary disea se within 6 months prior to 
consent including but not lim ited to the following:  
a. Unstable angina pectoris or myocardial infarction or elective c oronary intervention 
b. Congestive heart failure requiring hospitalization 
c. Uncontrolled clinically signifi cant arrhythmias, high grade atr ioventricular block 
(ie, Mobitz II or 3rd degree), pace maker, or implantable cardio verter-defibrillator. 
d. Pulmonary hypertension 
12. Abnormal and clinically significan t 12-lead ECG, including QT interval corrected for 
heart rate according to Frideri cia’s formula (QTcF) > 450 ms, Q RS interval ≥ 120 ms, 
PR interval > 220 ms, based on the average of triplicated ECG, assessed at Screening and 
the day prior to start of study t reatment. If any of these test results are out of range the test 
can be repeated once (in triplicate). 
13. Any condition affecting drug absorption, such as major surgery involving the stomach or 
small intestine (prior cholecystectomy is acceptable). 
14. Has received an investigational drug (including vaccines, excep t COVID-19 vaccine) 
within 5 times the elimination half-life (if known) or within 30 days (if the elimination 
half-life is unknown) prior to s tudy drug administration or is concurrently enrolled in any 
research judged not to be scientif ically or medically compatibl e with this study.  
15. Difficulty with venous access or unsuitable or unwilling to und ergo intravenous catheter 
insertion. 
16. Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude sa fe participation, confound study interpretation, interfere 
with compliance, or preclude informed consent. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 32  17. Received erythropoietin or other hematopoietic growth factor tr eatment within 28 days of 
signing ICF or is anticipated to require such agents during the  study. 
18. Ongoing or recent (within 2 years) substance abuse or positive alcohol/drugs of abuse 
results at Screening or the da y prior to the start of GBT021601  treatment. 
19. Known allergy to GBT021601 or other Hb polymerization inhibitor s. 
20. Current or recent use of voxelotor, crizanlizumab or L-glutamin e. Recent use is defined 
as within the past 3 months prior to the start of GBT021601 tre atment. 
21. Ongoing or recent use of strong inducers of CYP (cytochrome P45 0) 3A4/CYP3A5. 
Recent is defined as within 5 half-lives or 30 days, whichever is longer prior to the start 
of GBT021601 treatment. 
22. Ongoing or recent use of strong inh ibitors of CYP3A4/CYP3A5. Re cent is defined as 
within 5 half-lives pr ior to the start of GBT021601 treatment. 
23. Ongoing or recent use of the P-gly coprotein substrates digoxin and dabigatran. Recent is 
defined as within 5 half-lives  prior to the start of GBT021601 treatment. 
24. Use of a prohibited prescripti on or nonprescription drugs and dietary supplements 
(including herbal and alternative medications), as specified in  Section 6.5.2. 
25. Consumption of grapefruit and/or  grapefruit juic e within 14 day s prior to Day -1 and is 
unwilling to abstain from consumption of grapefruit and/or grapefruit juice until the 
EOS/ET. 
26. Any other condition or prior ther apy that, in the Investigator’ s opinion, would confound 
or interfere with the evaluat ion of or PK, safety, tolerability , and PD of the study drug, 
interfere with study compliance , or preclude informed consent. 
27. History of severe allergic reac tion (including anaphylaxis) to any substance, or previous 
status asthmaticus. 
5.2.1. Additional Exclusion Criteria (Part C): 
28. More than 10 VOCs within 10 months of Screening. 
29. For Part C of the study recent use of voxelotor is defined as w ithin 10 days prior to the 
start of GBT021601 treatment. 
30. Ongoing or recent use of strong or m oderate inducers of CYP3A4/ CYP3A5. Recent is 
defined as withing 5 eliminati on half-lives or 14 days, whichev er is longer prior to the 
start of GBT021601 treatment. 
31. Ongoing or recent use of strong or moderate inhibitors of CYP3A 4/CYP3A5. Recent is 
defined as within 5 elim
ination ha lf-lives prior to the start o f GBT021601 treatment. 
32. Consumption of Seville oranges within 14 days prior to the star t of GBT021601 
treatment and is unwilling to abs tain from consumption of Sevil le oranges until the 
EOS/ET Visit. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 33  33. History of overt stroke includi ng hemorrhagic stroke or transie nt ischemic attack (TIA) or 
spinal cord injury, magnetic res onance angiography (MRA)-define d vasculopathy, or 
magnetic resonance imaging (MRI)/t ranscranial doppler (TCD)-doc umented silent 
cerebral infarcts withi n 2 years of screening. 
34. Ongoing or recent (within 2 years) substance abuse (alcohol). 
35. Has received COVID-19 vaccine  (first dose, second dose, or boos ter dose), authorized by 
regional regulatory authority, w ithin 7 days prior to start of GBT021601 treatment. 
36. Has received an exchange tr ansfusion for a ny reason within 90 days prior to the start of 
GBT021601 treatment. 
5.3. Participant Re-Screening 
Participants who screen fail ma y be rescreened as long as the p articipant was not a screen fail 
due to noncompliance with the protocol (ie, positive urine drug s of abuse screen, etc). If the 
participant is re-screened, the  participant must again consent to participate in the study and a new 
Screening number must be used. All Screening assessments will b e repeated.  
5.4. Participant Withdrawal 
Participants are free to discontinue the study at any time, for  any reason, and without prejudice to 
further treatment. The Investig ator may remove a participant if, in the Investigator’s judgment, 
continued participation would pose unacceptable risk to the par ticipant or to the  integrity of the 
study data. All procedures for the  ET Visit must be completed. Reasons for removal or 
withdrawal may include: 
 Withdrawal of consent 
 Discretion of the Investigator/Sponsor 
 Participant noncompliance 
 Safety concern by the Inves tigator or the Sponsor 
Once dosed, participants who disc ontinue the study due to an AE  will not be replaced. 
Participants who discontinue the study due to reasons other tha n an AE or who have 
non-evaluable PK samples may be replaced at the discretion of t he Sponsor. 
In the event of a participant’s withdrawal, the Investigator wi ll promptly notify the Medical 
Monitor and Study Director and wi ll make every effort to comple te the Early Termination (ET) 
assessments. All withdrawn partic ipants with ongoing clinically  significant AEs/serious adverse 
events (SAEs) or laboratory findings will be followed until the  finding is resolved or medically 
stable; reasonable attempts will be made to follow-up with part icipants. 
5.5. Early Termination of Study 
The Sponsor has the right to ter minate this study at any time. Reasons for terminating the study 
may include, but are not limited t o, (1) the incidence or severity of AEs in this or  other studies 
indicating a potential health ha zard to participants, and (2) i n the Sponsor’s judgment, there are 
no further benefits to be achieved from the study.  
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 34  If the study is terminated earl y, the Sponsor shall inform all Investigators/institutions, regulatory 
authorities, and the Institu tional Review Board (IRB). 
5.5.1. Stopping Rules 
All participants will be closely monitored for any AEs by the site Investigator and the Sponsor’s 
Medical Monitor. The SMC will me et to review the Day 42 PK data  as well as safety and 
tolerability data prior to the  first and second dose escalation s in the multiple ascending dose 
period of the study. Additionall y, the SMC will meet on an ad h oc basis under any condition(s) 
where decisions about ongoing partic ipant dosing in the study i s in question and participant 
safety may be at risk. Criteria that may warrant an ad hoc SMC meeting include, but are not 
limited to the following:  
1. A participant experiences any AE Grade ≥ 2 or SAE. 
2. A participant experiences worsening of an ongoing AE by ≥ 1 grade. 
3. A participant experiences any other finding (symptoms, physical  examination, 
laboratory) whose severity ma y preclude dosing new participants  in the study. 
AEs will be graded based on National Cancer Institute’s Common Toxicity Criteria Scale 
(NCI CTCAE v5). The individual part icipant’s tole rability to th e study drug will be determined 
based on the criteria provided be low. Individual Dose Stopping Rules 
Dosing for any individual participant will be stopped if the pa rticipant experiences a SAE or a 
clinically significant nonser ious AE, which in the opinion of t he Principal Investigator or 
Sponsor’s Medical Monitor, warrants discontinuation of the stud y for that participant’s well-being. 
5.6. Safety Monitoring Committee 
The sites’ Principal Investigator s and the Sponsor’s Medical Monitor will closely monitor the 
safety of the study participants throughout the duration of study. The SMC will review the 
totality of safety, tolerability, and available PK and PD data to monitor safety. 
The SMC will be composed of the P rincipal Investigators from ea ch site, or designee, and 
Sponsor representatives, includ ing the Medical Monitor, Clinica l Pharmacologist, Biostatistician, 
and Product Safety Officer and/or Product Safety Medical Scientist. The SMC will have overall 
responsibility for any safety and tolerability decisions and fo r proceeding with dose escalation. 
Details of the scope including decision, responsibilities, acti on taken, and frequency of the SMC 
will be provided in the SMC charter. 
In the Multiple Ascending-dose Period of the study, the SMC will review safety, tolerability, PK, 
and PD data through Day 42 after the  single dose from at least 4 participants. The Sponsor will 
inform the SMC in writing regar ding the GBT021601 half-life, an d dosing interval of 
steady-state multiple dosing for the participants of this study .  
For the Extended treatment peri od (Part C), the SMC will meet o n an ad hoc basis under any 
condition(s) where decisions about ongoing participant dosing in the study is in question and 
participant safety may be at risk. 
This is an open label study, so the data reviewed to make dose escalation decisions will not be 
blinded.  
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 35  5.7. Dose Escalation Criteria 
The % Hb occupancy by GBT021601 will  be calculated from the PK as the ratio of GBT021601 
concentration to the Hb (estimat ed at 5mM) in RBCs. The Hb% mod ification will be based on 
hemoximetry data. The Hb% occupancy/modification will be utiliz ed as a PD marker because it 
is a measure of target engagement that has been employed in pri or clinical studies of hemoglobin 
modifying agents.  
Dose escalation will be pharmacologically guided (based on PK a nd PD target levels, Table 6 ). 
Dose escalation will proceed after review of safety, tolerability, PK, and PD data through 
Day 42. Dose escalation will stop according to the stopping rules (Section 5.5.1). Dose escalation 
will proceed (no more than 2-fold increments) beginning with th e Dose 1 with a predicted target 
of ~20% to 30% Hb occupancy/modi fication and Dose 2 with a pred icted target of > 30% Hb 
occupancy/modification.  
Concerns over potential acute mechanism-related toxicities (tis sue hypoxia) are related to the 
peak achieved % Hb occupancy and therefore to the maximum plasm a concentration (C max). 
For this reason, prior to initiating multiple doses, safety, to lerability, PK, and PD data will be 
reviewed by the SMC. Prior to dose escalation, dose levels may be revised if indicated, based on 
PK/PD data.  
Progression to the next higher dose will only occur if the prev ious dose level was deemed by the 
SMC to be safe and well tolerated. 
When it is not appropriate to es calate the dose, then the same dose or a titrated dose may also be 
investigated depending upon the results of the safety data from the previous dose levels. 
 
Table 6: Target % Hb Occupancy/Mo dification for Multiple Ascend ing-dose Period, 
Intrapatient Dose Escalation  
Dose Escalation 
Level Predicted % Hb 
Occupancy/Modification Anticipated Loading 
Dose (mg)a Anticipated Maintenance  
Dose (mg)a 
Dose 1 ~20% to 30% TBD TBD every TBD 
Dose 2 > 30% TBD TBD every TBD 
a The GBT021601 dose levels and fr equency to be evaluated will be  determined based on PK/PD evaluation of 
single doses in healthy volunteers and Day 42 PK in adults with  SCD . 
 
Based on the findings from Dose  Levels 1 and 2, there were no s ignificant safety concerns 
related to GBT021601 and based on PPK modeling, the planned dos es are expected to result in 
Hb occupancy of approximately 54%.   
 
Table 7: Model-Predicted Dose Planned for Extended Treatment Pe riod 
Loading Dose Maintenance Dose Mean Targeted % Hb 
Occupancy 
300 mg BID x 4 days 
 150 mg QD ~54% 
 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 36  6. TREATMENT OF PARTICIPANTS 
6.1. Description of Study Drug 
Study drug details are presented in Table 8 .  
 
Table 8: Identity of Study Drugs 
Study Drug Dosage Form Strength 
GBT021601 Tablet 100 mg 
GBT021601 Capsule 5 mg, 25 mg 
 As of Protocol Amendment 5, study drug will be provided as a ta blet or capsule as per Table 9 . 
 Table 9: Study Drug for Extended Treatment Period 
Study Drug Dosage Form Dose Strength 
GBT021601 Tablet 100 mg 
GBT021601 Capsule 25 mg 
 GBT021601 tablets and capsules will be provided by the Sponsor.  
6.2. Treatments Administered 
Study drug will be administered orally with approximately 240 m L non-carbonated room 
temperature water. 
6.3. Method of Assigning Participants to Treatment Groups 
This is an open-label, single-arm, intrapatient, single dose an d multiple dose escalation study. 
Participants will be assigned a study identification number during Screening and a separate 
number assigned at enrollment. 
6.4. Measurements of Treatment Compliance 
The first dose of the study drug will be administered by delega ted and trained staff at the clinical 
research unit (CRU). Details r egarding dosing, including the do se administered and the date and 
time of dosing, will be recorded in a dosing diary during the maintenance doses. Additionally, 
a hand and mouth check will be performed to verify that the adm inistered dose was swallowed. 
For the Multiple Ascending-dose Period of this trial, at Week 8  and Week 13 Visits, the loading 
dose (as applicable) will be a dministered by delegated and trai ned staff at the CRU. Details 
regarding dosing, including the dos e administered and the date and time of dosing, will be 
recorded. Maintenance doses will be administered either by the CRU staff during visits or by the 
participant based on the to be determined frequency of dosing. Recording of dosing to monitor 
compliance will also be based on the dosing frequency. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 37  6.5. Concomitant Medications, Procedures, Other Restrictions and 
Requirements 
6.5.1. Concomitant Medications and Procedures 
Study participants will be allowed to take other medications as  needed with the exception of 
those described listed in Section 6.5.2 . All concomitant medications will be documented. 
In the interests of participant safety and acceptable standards of medical care the Investigator 
will be permitted to prescribe treatment(s) at his/her discreti on. All treatments must be recorded 
in the participants’ electronic case report form (eCRF) (medica tion, dose, treatment duration and 
indication). 
6.5.2. Other Restrictions 
Participants will be instructed t o adhere to the following rest rictions: 
 Participants are not permitte d to use drugs of abuse from Screening through EOS/ET 
Visit. 
 Participants are not permitted to use herbal preparations or di etary supplements, 
or any drugs that induce or inhib it study drug-specific CYP(s) within 14 days or 
5 half-lives, whichever is  longer, prior to Day -1. 
 Participants are not permitte d to use voxelotor, crizanlizumab, or L-glutamine while 
participating in this clinical study. 
 Participants are not permitted to consume grapefruit and/or gra pefruit juice from 
14 days prior to Day -1 through the EOS/ET Visit. 
 During the Single-dose Period, participants are not permitted t o consume any food 
and drink from outside of the CRU while residing at the CRU. 
 Participants are not permitted to participate in any other inte rventional clinical study 
or donate blood or plasma while part icipating in this clinical study. 
6.5.3. Fertility and Contraceptive Requirements 
6.5.3.1. Female Participants of C hildbearing Potential 
Refer to Inclusion Criterion 6. 
Female participants who are of child-bearing pote ntial are requ ired to use highly effective 
methods of contraception. 
Highly effective contraception m ethods are defined as the follo wing: 
a. Estrogen and progestogen containi ng hormonal contraception asso ciated with 
inhibition of ovulation OR progest ogen only hormonal contracept ion associated with 
inhibition of ovulation by oral, implantable, or injectable rou te of administration 
b. An intrauterine device (IUD) 
c. An intrauterine hormone-releasing system (IUS) 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 38  d. Females with bilateral tubal occlusion 
e. Surgically sterile male partner (eg, vasectomy) 
f. True sexual abstinence, define d as refraining from heterosexual  intercourse during the 
entire period of risk associate d with the study treatments. Periodic abstinence 
(eg, calendar, ovulation, symptom-thermal, post-ovulation metho ds), and withdrawal 
are not acceptable methods of contraception. 
6.5.3.2. Instructions for Male Participan ts Capable of Fathering a Child 
There is no information about effects that GBT021601 could have  on male sperm and on the 
development of the fetus in humans. Therefore, it is important that the female partners of male 
participants do not become pre gnant during the study and for a total period of 165 days after the 
male participant has taken the last dose of GBT021601. 
As a precaution, all male participants who are sexually active and not surgically sterile should 
avoid fathering a child by either  true abstinence or the use of  barrier methods of contraception 
plus highly effective contracep tion for their female partner if  of childbearing potential.  
6.5.3.3. Acceptable Forms of Contraception for Male Participants with Female Partners 
Capable of Reproduction 
Refer to Inclusion Criterion 6. 
Male participants who are not sur gically sterile with partners of childbearing potential must 
agree to use a highly effective method of birth control during the study and for 165 days after the 
last dose of study drug. A highl y effective method of contracep tion is defined as one that results 
in a low documented failure rat e when used consistently and cor rectly such as: condom plus use 
of an intrauterine device; intr auterine system or hormonal meth od of contraception 
(oral, injected, implanted, or tra nsdermal) for their female pa rtner; or sexual abstinence. 
Male participants who are not sur gically sterile with a partner who is pregnant must agree to 
condom use or maintain sexual ab stinence during the study and f or 165 days after the last dose of 
study drug. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 39  7. STUDY DRUG MATERIALS AND MANAGEMENT 
7.1. Study Drug 
GBT021601 will be provided as a tablet formulation in the strength of 100 mg and a capsule 
formulation in strengths of 5 mg and 25 mg. All excipients used  are compendial grade and are 
listed in the FDA’s Inactive Ingr edients Database. As of Protocol Amendment 5, GBT021601 
will be provided as a 100 mg tablet or a 25 mg capsule. 
7.2. Study Drug Packaging and Labeling 
GBT021601 will be provided in high density polyethylene (HDPE) bottles of 30 tablets and in 
separate HDPE bottles of 30 capsule s with child resistant caps with induction seal and labeled 
according to local regulations.  
7.3. Study Drug Storage 
Study drug will be stored at controlled room temperature betwee n 15°C to 25°C in the storage 
area of the investigational site  pharmacy, which is a secure, t emperature controlled, locked 
environment with restricted access. 
No special considerations for  safe handling of GBT021601 are required. 
7.4. Blinding of Treatment Assignment 
Not applicable since this  is an open-label study. 
7.5. Administration 
GBT021601 will be administered orally. For the single-dose peri od, participants wil l fast at least 
10 hours before and for at least  4 hours after study drug admin istration. Water will be allowed as 
desired except for 1 hour befo re and 1 hour after study drug ad ministration.  
For the multiple ascending-dose period of the study, GBT021601 can be taken with or without 
food.  Each dose will be administered orally with approximately 240 mL  of water (additi onal water to 
complete dosing is allowed). Parti cipants will be instructed to  swallow the tablets or capsules 
within 5 minutes. If the participant vomits, the dose should no t be repeated. 
7.6. Study Drug Accountability and Disposal 
The Investigator must ensure  that all study drug supplies are k ept in a secure locked area with 
access limited to those authorized by the Investigator. The Inv estigator must maintain accurate 
records of the receipt of a ll study drug shipped by the Sponsor  or their representative, including 
but not limited to the date rece ived, lot number, amount receiv ed, and the disposition of all study 
drug. Current dispensing records will also be maintained includ ing the date and amount of study 
drug dispensed and the participa nt receiving the study drug. Al l remaining study drug not 
required by regulations to be held by  the CRU must be reconcile d prior to destruction. Drug may 
be returned to the Sponsor’s repre sentative immediately after t he study is completed or destroyed 
on-site with Sponsor approval. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 40  8. PHARMACOKINETIC AN D PHARMACODYNAMIC 
ASSESSMENTS 
8.1. Blood Sample Collection 
The PK/PD samples for GBT021601  will be collected at time point s specified in the PK/PD 
sampling schedules (Table 1 , Table 2 , Table 3,  and Table 4 ). Sample collection, processing, and 
shipping details will be outlined in a separate study reference  manual. 
For procedures scheduled to be performed at the same time, prio rity is to be given to collection 
of the PK samples at the designated time. ECGs, followed by vital signs, are to be performed 
before PK sampling unless PK sampl es will be delayed as a resul t.  
8.1.1. Single-dose Period 
During the Single-dose Period, p lasma and whole blood PK sample s will be collected at the 
following times: 
Pre-dose (within 60 minutes of dosing) and postdose at 0.25, 0. 5, 1, 2, 4, 6, 8, 12 hours; 24 hours 
(Day 2), 36 hours, 48 hours (Day 3), and 72 hours (Day 4); Days  7, 14, 21, 28, and 42. 
The windows for sample collection are provided in Table 10 . 
 
Table 10: Windows for PK Sample Collection – Single-dose Period  
Sample Collection Time Allowed Deviation 
0.0 – 1.0 hour  ± 2 minutes  
> 1.0 – 24.0 hours  ± 5 minutes  
> 24.0 – 72.0 hours  ± 10 minutes  
> 72.0 – 144.0 hours ± 15 minutes 
> 144.0 hours ± 24 hours 
 Blood samples for hemoximetry and RBC deformability, dense cell s will be collected at the 
same time as the PK samples at pre-dose and 12 hours postdose o n Day 1. In addition, 
hemoximetry samples will be collected on Days 2, 4, 7, 21, and 42. 
8.1.2. Multiple Ascending-dose Period 
Plasma and whole blood pre-dose and postdose PK samples will be  collected in the Multiple 
Ascending-dose period as listed in Table 11 . Whole blood samples for hemoximetry and RBC 
deformability, dense cells will be c ollected at the same time a s the PK samples. 
 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 41  Table 11: PK and PD Sample Collection Times – Multiple Ascending-dose Period 
Week Pre-dosea Postdose 
8 1 PK/PD sample Pre-dose 1 PK sample between 0.25 hour to 1 ho ur 
1 PK/PD sample between 2 to 4 hours 
9 1 PK/PD sample Pre-dose 1 PK sample between 0.25 hour to 1 ho ur 
1 PK/PD sample between 2 to 4 hours 
10 1 PK/PD sample Pre-dose 1 PK sample between 0.25 hour to 1 h our 
1 PK/PD sample between 2 to 4 hours 
11 1 PK sample Pre-dose 1 PK sample between 0.25 hour to 1 hour ,  
1 PK/ sample between 2 to 4 hours 
12 1 PK sample Pre-dose 1 PK sample between 0.25 hour to 1 hour  
1 PK sample between 2 to 4 hours 
13 1 PK/PD sample Pre-dose 1 PK sample between 0.25 hour to 1 h our 
1 PK/PD sample between 2 to 4 hours 
14 1 PK sample Pre-dose 1 PK sample between 0.25 hour to 1 hour  
1 PK sample between 2 to 4 hours 
15 1 PK sample Pre-dose 1 PK sample between 0.25 hour to 1 hour  
1 PK sample between 2 to 4 hours 
16 EOT 1 PK/PD sample Pre-dose 1  PK sample between 0.25 hour to  1 hour 
1 PK/PD sample between 2 to 4 hours 
EOS/ET  Anytime during visit 
 
Abbreviations: PD, pharmacodynamics; PK, pharmacokinetics. 
a The pre-dose blood sample for PK and PD assessments should be collected within 30 minutes prior to dosing. 
 
Table 12: PK and PD Sample Coll ection Times –Extended Treatment  Period  
Extended Treatment Period Pre-dosea P ostdose 
Week Day  
1 1 1 PK/PD sample  1 PK sample between 0.25 hour to 1 hour 
1 PK/PD sample between 2 to 4 hours 
2 15 1 PK/PD sample  1 PK sample between 0.25 hour to 1 hour 
1 PK/PD sample between 2 to 4 hours 
4 29 1 PK sample  1 PK sample between 0.25 hour to 1 hour 
1 PK sample between 2 to 4 hours 
6 43 1 PK sample  1 PK sample between 0.25 hour to 1 hour 
1 PK sample between 2 to 4 hours 
10 71 1 PK sample  
 
14  98 1 PK sample  
 
Final Visit Anytime during visit 
 
Abbreviations: PD, pharmacodynamics; PK, pharmacokinetics.  
a The pre-dose blood sample for PK and PD assessments should be collected within 30 minutes prior to dosing. 
 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 43  
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 44  9. ASSESSMENT OF SAFETY 
9.1. Safety Parameters 
9.1.1. Demographic/Medical History 
The Investigator or designee will collect a complete medical an d surgical history at Screening 
and again at CRU admission to dete rmine if any changes have occ urred since Screening. 
9.1.2. Vital Signs 
Vital signs assessments will include respiratory rate (breaths per minute), systolic and diastolic 
BP (mmHg), and heart rate (HR) (beats per minute [bpm]) and bod y temperature, which will be 
measured after a participant has rested for at least 5 minutes in the supine position as per Table 1,  
Table 2 , Table 3, and Table 4.   
Any clinically significant abnor mal vital sign assessment requi res at least 1 repeat measurement.  
Vital signs abnormalities that are  (1) considered clinically significant initially and on 
confirmation, (2) require a partic ipant to be discontinued from  the study, (3) req uire a participant 
to receive treatment, or (4) re quire a change or discontinuatio n from the study drug 
(if applicable) will be recorded as AEs. 
9.1.3. Weight and Height 
Height will be completed at Screening only and weight as per Table 1,Table 3, and Table 4. 
9.1.4. Physical Examination 
A full physical examination will be conducted at Screening. All  subsequent physical 
examinations should be signs and symptoms driven. Full physical examination will include 
examination of the following: ge neral appearance, head, ears, eyes, nose, throat, neck, skin, 
cardiovascular system, respirato ry system, gastrointestinal sys tem, musculoskeletal system, 
lymph nodes, and nervous system (Table 1 ,Table 3,  and Table 4 ). 
An abnormal physical examination finding during the on-study pe riod (ie, following dose 
administration) that is consider ed clinically significant and ( 1) requires the participant to be 
discontinued from the study, or (2)  requires the participant to  receive treatment will be recorded 
as an AE. 
9.1.5. Electrocardiogram 
Electrocardiograms (ECG) (12-lead ) will be collected in triplic ate within 5 minutes as per 
Table 1 , Table 2 , Table 3, and Table 4.  
ECGs will be recorded after a par ticipant has rested at least 5  minutes in the supine position. 
The following ECG parameters will  be recorded: HR, PR, QRS, QT,  and QTcF intervals.  
ECG assessment will include interpretation of th
e tracings (eg, rhythm, presence of arrhythmia 
or conduction defects, any eviden ce of myocardial ischemia/infarction, or ST segment, T-wave, 
and U-wave abnormalities). The Investigator or designee is resp onsible for reviewing and over-
reading the ECG interpretati on, for assessing whether the ECG m achine interpretation findings 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 45  are accurate, appropriate, nor mal, or abnormal, and for providi ng corrected interpretations as 
appropriate. In addition, any abnormal ECGs will be assessed fo r clinical significance. 
Additional ECGs may be obtained i f clinically indicated and mus t be obtained if abnormal and 
clinically significant or thought  to be an error (eg, lead plac ement error, movement artifact, etc.). 
Any additional relevant data obtained by the Investigator durin g the course of this study will be 
supplied to the Sponsor. 
For any ECG that the Investigator  considers clinically signific ant, the Investigator will: 
 Repeat the ECG. 
 Follow-up ECG(s) will be obtained if any significant abnormalit ies are detected after 
dose administration to document resolution and as clinically in dicated. 
 Record as an AE any ECG that is  1) confirmed by the Investigato r as clinically 
significant, 2) requires a part icipant to be discontinued from the study, or 3) requires a 
participant to receive treatment. 
9.1.6. Laboratory Assessments 
9.1.6.1. Standard Clinical Laboratory Assessments 
Clinical laboratories described in Table 13 will be collected as outlined in Table 1  and Table 3, 
and Table 4 . A certified laboratory will be  utilized to process and provid e results for the clinical 
laboratory tests. The Baseline laboratory test results for clin ical assessment for a particular test 
will be defined as the last measurement prior to the first dose  of study drug. 
During Screening, if a participan t has an out-of-range value fo r a clinical laboratory parameter 
that the Investigator believes is not clinically significant or  that the Investigator does not believe 
is correct (eg, laboratory or  specimen processing error), but t he Investigator wants to confirm 
with a repeat laboratory test, a  single repeat is allowed to co nfirm the initial result. 
All out of-range values will be assessed by the Investigator as  clinically significant or not 
clinically significant. For any l aboratory test value outside t he reference range that the 
Investigator considers clinical ly significant during the on-stu dy period (ie, following dose 
administration), the Investigator  will repeat the test to verif y the out-of-range value and clinical 
significance. 
Additional safety laboratory t ests may be conducted as needed b y the Investigator to evaluate 
participant safety. 
9.1.6.2. Other Laboratory Assessments 
Assessments of p50 and p20 will be conducted by hemoximetry as indicated in Table 1, Table 3, 
and Table 4  . Assessments of RBC deformability and dense cells will be con ducted as indicated 
in Table 1 , Table 3,  and Table 4.  
Assessments of serum erythropoietin (EPO) will 
be conducted as indicated in Table 1 and 
Table 3, and Table 4. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 48  10. ASSESSMENT OF SAFETY — ADVERSE EVENTS 
10.1. Adverse and Serious Adverse Events 
10.1.1. Definition of Adverse Events 
An AE is defined as any untoward m edical occurrence associated with the use of a drug in 
humans, whether or not consider ed related to the study drug. An  AE can therefore be any 
unfavorable and unintended sign, s ymptom, or disease temporally  associated with the use of a 
study drug. An AE may also constitute complications occurring as a result of protocol-mandated 
interventions (eg, invasive proced ures such as biopsies), inclu ding the period prior to receiving 
the first dose of the study dr ug (eg, medication washout). In a ddition to new events, any increase 
in the severity or frequency of a pre-existing condition occurring after the participant signs the ICF is considered to be an AE. T his includes any side effect, i njury, toxicity, or sensitivity 
reaction. 
A suspected adverse reaction is a ny AE for which there is a rea sonable possibility that the drug 
caused the AE. For the purposes of expedited safety reporting, “reasonable possibility” means 
there is evidence to suggest a ca usal relationship between the drug and the AE. Suspected 
adverse reaction implies a lesse r degree of certainty about cau sality than adverse reaction, 
which means any AE caused by a drug. 
A life-threatening AE or life-th reatening suspected adverse rea ction is an AE or suspected 
adverse reaction that, in the view of either the Investigator o r Sponsor, places the study 
participant at immediate risk of  death. It does not include an AE or suspected adverse reaction 
that, had it occurred in a more se vere form, might have caused death. 
An AE or suspected adverse reaction is considered to be “unexpe cted” if it is not listed in the 
Reference Safety Information sect ion of the current IB or is no t listed at the specificity or 
severity that has been observed. 
10.1.2. Serious Adverse Event 
A SAE or serious suspected adverse reaction is an AE or suspected adverse reacti on that, at any 
dose, in the view of either the I nvestigator or Sponsor, result s in any of the following outcomes: 
 Death; 
 A life-threatening AE; 
 Inpatient hospitalization or prolongation of existing hospitali zation; 
 Persistent or significant incapacity or disability (substantial  disruption of the ability to 
conduct normal life functions); 
 A congenital anomaly/birth defect; or 
 Important medical events that  may not result in death, be immed iately 
life-threatening, or require hospi talization may be considered serious when, based 
upon medical judgment, they may jeopardize the study participant and may require 
medical or surgical interventi on to prevent one of the outcomes listed in this 
definition. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 49  Note: Hospitalization planned prior to study enrollment (eg, fo r elective surgeries) is not 
considered to be an SAE. Hospitali zations that occur for pre-ex isting conditions that are 
scheduled after study enrollment are considered SAEs. 
10.2. Severity 
Whenever possible, the severity of all AEs will be graded using  the National Cancer Institute 
Common Terminology Criteria for A dverse Events (NCI CTCAE), Ver sion 5.0. 
For AEs not adequately addressed in the NCI CTCAE, Version 5.0,  the following criteria should 
be used. 
 Grade 1 – Mild: Asymptomatic or mild symptoms; clinical or diag nostic observations 
only; interventi on not indicated. 
 Grade 2 – Moderate: Minimal, lo cal or noninvasive intervention indicated; 
limited age-appropriate instrumental activities of daily living  (ADLs). 
 Grade 3 – Severe: Medically significant but not immediately lif e-threatening; 
hospitalization or prolongation of  hospitalization indicated; d isabling; 
limiting self-care ADLs. 
 Grade 4 – Life-threatening: Life- threatening consequences; urge nt intervention 
indicated. 
 Grade 5 – Fatal: Death. 
To make sure that there is no confusion or misunderstanding bet ween the terms “serious” and 
“severe”, which are not synonymous, the following note of clari fication is provided. The term 
“severe” is often used to describe the intensity (severity) of a specific event (ie, mild, moderate, 
or severe); the event itself, how ever, may be of relatively min or medical significance (eg, severe 
headache). This is not the same as “serious”, which is based on  the study participant/event 
outcome or action criteria associ ated with events that pose a t hreat to a particip ant’s life or 
functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting 
obligations. 
10.3. Relationship to Study Drug 
The relationship of an AE to t he study drug should be determine d by the Investigator according 
to the following definitions: 
 Not Related : Evidence exists that the AE ha s an etiology other than the st udy drug 
and/or the temporal relationship of the AE/SAE to the study dru g administration 
makes the relationship unlikely. If an SAE is not considered to  be related to study 
drug, then an alternative explan ation should be provided. 
 Related : A temporal relationship exis ts between the event onset and th e 
administration of the study drug and makes a causal relationshi p possible or probable. 
It cannot be readily explained by t he participant’s clinical st ate or concomitant 
therapies and may appear, with som e degree of cer tainty, to be related based on the 
known therapeutic and pharmacol ogic actions of the drug. Good c linical judgment 
should be used for determining causal assessment. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 50  10.4. Unexpected Adverse Reactions 
An AE is “unexpected” if its nature and severity are not consis tent with the information about the 
study drug provided in the Referen ce Safety Information in the IB. 
10.5. Recording Adverse Events 
10.5.1. General 
All AEs will be record ed from the time the  study participant signs the ICF form until the EOS 
Visit or ET Visit, whichever com es first. All AEs must be repor ted on the AE electronic case 
report form (eCRF) via the electronic data capture system. The Investigator is responsible for 
evaluating all AEs, obtaining supporting documents, and ensuring that documentation of the 
event is complete. Details of each reported AE must include at a minimum severity, relationship 
to study treatment, duration, a nd outcome. All serious and nonserious AEs must be followed 
until they are resolved or stabilized, or until reasonable atte mpts to determine resolution of the 
event are exhausted. 
Any participant who experiences an AE may be discontinued from study treatment at any time at 
the discretion of the Investigat or. The Sponsor/Medical Monitor (s) must be notified of the study 
participant discontinuation. 
10.5.2. Diagnosis Versus Signs and Symptoms 
If known, a diagnosis should be recor ded in the eCRF rather tha n individual signs and symptoms 
(eg, record only liver failure or hepatitis rather than jaundic e, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or sym ptoms cannot be medically 
characterized as a single diagnosis or syndrome at the time of reporting, each individual event 
should be recorded separately i n the eCRF. If a diagnosis is su bsequently established, it should 
be reported as follow-up information. 
10.5.3. Abnormal Laboratory Values 
Clinically significant laboratory abnormalities will be recorde d in the AE eCRF 
(eg, abnormalities that have clinic al sequelae, more frequent f ollow-up assessments, or further 
diagnostic investigation). If th e clinically significant labora tory abnormality is a sign of a disease 
or syndrome (eg, alkaline phosphatase and bilirubin 5 × ULN associated with cholecystitis), 
only the diagnosis (eg, cholecys titis) should be recorded in th e eCRF. 
If the clinically significant laboratory abnormality is not a s ign of a disease or syndrome, 
the abnormality itself should be recorded on the eCRF. If the l aboratory abnormality can be 
characterized by a precis e clinical term, the  clinical term should be recorded. For example, 
a serum potassium level of 7.0 mEq/L should be recorded as “hyp erkalemia”. 
Observations of the same clinic ally significant laboratory abno rmality from visit to visit should 
not be repeatedly recorded on the  AE eCRF, unless their severit y, seriousness, or etiology 
changes. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 51  10.6. Reporting Adverse Events 
10.6.1. Serious Adverse Events 
All SAEs, regardless of causal attribution, must be reported by  the Investigator or designee or 
site personnel with in 24 hours of awarene ss by completing the p aper SAE report forms and 
submit via fax or email to Sponsor’s Pharmacovigilance or designated CRO. 
The Sponsor or designee may request additional source documenta tion pertaining to the SAE 
from the investigational site. F ollow-up reports must be submitted within 24 hours of awareness, 
and participant identif ier information (eg, name, medical record number) must be redacted in the 
hospital discharge summaries, au topsy reports, and/or death certificates. 
Follow-up SAE information must be submitted within 24 hours of awareness as additional 
information becomes available. A ll SAEs regardless of causal at tribution must be followed to 
resolution or stabilization, or until reasonable attempts to determine resolution of the SAE are 
performed. 
Investigators are not obligated to actively seek SAE informatio n from participants that complete 
the study, but investigators are encouraged to notify the Sponsor, or designee, of any SAEs of 
which they become aware occurring at any time after a participa nt has discontinued or completed 
the study that they judge may be  reasonably related to treatmen t with study drug or study 
participation. 
10.6.2. Reporting Suspected Unexpected Serious Adverse Reactions and Ur gent Safety 
Issues 
The Sponsor or designee is respon sible for reporting suspected unexpected serious adverse 
reactions (SUSARs) to regulatory a gencies, competent authorities, IRB, and Investigators as per 
local laws and regulations. Fatal  and life-threatening SUSARs w ill be submitted no later than 
7 calendar days of the Sponsor’s  or designee’s first knowledge of the event and follow-up 
information submitted within an a dditional 8 calendar days, or as otherwise requi red per local 
laws and regulations. All other SUSARs will be submitted within 15 calendar days of the 
Sponsor’s or designee’s first know ledge of the event. The Inves tigator is responsible for 
notifying the local IRB of all SAEs that occur at his or her site as required by local regulations or 
IRB policies, if this responsibility resides with the site. 
Investigators are required to re port any urgent safety matters to the Sponsor or designee within 
24 hours of awareness. The Sponsor or designee will inform regu latory authorities, IRBs, and 
Investigators, as applicable, of  any events (eg, change to the safety profile of GBT021601, major 
safety findings that may place study participants at risk) that  may occur during the clinical study 
that do not fall within the defini tion of a SUSAR but may adversely affect the safety of study 
participants. 
10.7. Pregnancy 
If a participant becomes pregna nt while on study, the pregnancy  must be reported to the Sponsor 
or designee within 24 hours of awa reness. The Investigator will  discuss the risks and concerns of 
study drug exposure to a developing fetus and counsel the parti cipant and/or pr egnant partner 
(or ensure such counseling is provided). 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 52  Reported pregnancy of a participan t while participating in this  study will be monitored for the 
full duration of the pregnanc y, and/or followed through a definitive outcome (ie, birth or 
spontaneous or elective aborti on). Pregnancies in partners of m ale study participants will 
similarly be monitored for the f ull duration of the pregnancy and/or followed through a definitive 
outcome (ie, birth or spontane ous or elective abortion). 
An uncomplicated pregnancy will not be considered an AE or SAE.  Pregnancy complications 
such as spontaneous abortion/mis carriage and congenital anomali es are considered SAEs and 
must be reported as described in Section 10.6.1. Note that an elective abortion is not considered 
an SAE. Pregnancy and pregnancy o utcomes must be reported on a Pregnancy Notification 
Form or Pregnancy Outcome Form, r espectively, and sent to the S ponsor or designee within 
24 hours of the Investigator sit e personnel learning of the pre gnancy or pregnancy outcome.  
The child born to a female partic ipant or partner of a male par ticipant exposed to study drug will 
be followed for 3 months after  delivery. The outcome of any pregnancy and the presence or 
absence of any congenital abnormality will be recorded in the P regnancy Outcome Form and 
reported to the Sponsor or designee. Any congenital abnormalities in the offspring will be 
reported as an SAE and must be rep orted as described in Section  10.6.1.  
Information regarding pregnancy testing (including definition o f females of childbearing 
potential) is provided in Section 6.5.3 . Highly effective means of contraception are 
listed in Section 6.5.3.3. 
10.8. Drug-induced Liver Injury 
Participants will be monitored f or signs of drug-induced liver injury (DILI).  
Potential events of DILI will be defined as meeting all the following criteria (as specified in the FDA Guidance for Industry: Drug-Induced Liver Injury: Prem arketing Clinical Evaluation . 
[FDA, 2009 ]):  
 ALT > 4 × ULN or aspartate aminotransferase > 3 × ULN 
 No other reason can be found to explain the combination of labo ratory value 
increases (eg, acute viral hepati tis; alcoholic and autoimmune hepatitis; hepatobiliary 
disorders; nonalcoholic steatohepa titis; cardiovascular causes;  concomitant 
treatments) 
Potential events of DILI will  be reported as SAEs (Section 10.6.1). All participants with 
potential DILI will be closely followed until abnormalities ret urn to normal or baseline or until 
all attempts to determine resolu tion of the event are exhausted . 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 53  11. STATISTICS 
Study data will be reported using summary tables, figures, and listings. Study analyses will be 
descriptive in nature and no formal statistical tests are plann ed. 
11.1. Sample Size Calculation 
Due to the exploratory nature  of this study, no formal power or sample size calculations were 
used to determine cohort size . A sample size of up to 6 partici pants with SCD are expected to 
provide adequate character ization of PK and safety. 
11.2. Analysis Populations 
Safety Population: All participants who received study drug. 
Pharmacokinetic Full Population: All participants who received study drug and have at least 
1 concentration data point (plasma or whole blood). 
Pharmacokinetic Evaluable Population: All participants who received study drug and have a 
sufficient PK profile to derive at least 1 PK parameter. 
11.3. Interim Analysis 
There is no formal planned interim analysis.  
11.4. Safety Analysis 
AEs will be coded to system organ class and preferred term usin g the Medical Dictionary for 
Regulatory Activities (MedDRA)  and summarized. Vital signs and laboratory safety assessments 
will be presented with identif ication of values outside of norm al range. Electrocardiogram data 
will be presented, wit h any clinically relev ant abnormal findin gs or changes highlighted. 
11.5. Pharmacokinetic Analysis 
Noncompartmental PK analysis o r population PK analysis using nonlinear mixed-effect 
modeling will be performed to characterize GBT021601 PK in plasma, and whole blood 
following single and multiple doses.  
11.6. Pharmacodynamic Analysis 
Pharmacodynamic markers and comput ed PD parameters will be list ed. Individual and mean PD 
marker data will be presented graphically.  
  
11.7. Pharmacokinetic/Pharmacodynamic Relationships 
The relationships between PK and PD may be explored by PK/PD mo deling, if appropriate. 
Results of these analyses will be presented in a separate repor t. 
CCI
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 54  12. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
The Investigator will permit study-related monitoring, audits, IRB review, and regulatory 
inspection, as appropriate, by provi ding direct access to sourc e data/documents. 
12.1. Source Data 
Original documents, data, records (eg, clinic records, laborato ry notes, memoranda, participant 
diaries or evaluation checklis ts, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcrip tions certified after verificat ion as being accurate and complete, 
participant files, and records ke pt at the pharmacy, laboratori es, and medico-technical 
departments involved in the clinical study), and all relevant s ections of the participant’s medical 
records and all other data coll ection made specific to this stu dy constitute source documents. 
Before an investigational site can enter a participant into the  study, a representative of Sponsor 
and/or designee will visit the CRU to: 
 Determine the adequacy  of the facilities; and 
 Discuss with the Investigator a nd other personnel their responsibilities with respect to 
protocol adherence, and the res ponsibilities of the Sponsor or its representatives. 
This will be documented in a Clinical Study Agreement between t he Sponsor and the 
Investigator. 
During the study, a monitor from t he Sponsor or representative will have regular contact with the 
investigational site , for the following: 
 Provide information and support to the Investigator(s). 
 Confirm that facilities remain acceptable. 
 Confirm that the investigational team is adhering to the protoc ol that data are being 
accurately recorded in the eCRF, and that study drug accountabi lity checks are being 
performed and dosing diaries reviewed. 
 Perform source data verificati on. This includes a comparison of  the data in the eCRF 
with the participant’s medical  records at the  hospital or pract ice, and other records 
relevant to the study. This will require direct access to all o riginal records for each 
participant (eg, clinic charts). 
 Record and report any p rotocol deviations no t previously sent t o the Sponsor. 
 Confirm AEs and SAEs have been properly documented on eCRFs and  confirm any 
SAEs have been forwarded to the Sponsor or safety designee and those SAEs that met 
criteria for reporting have b een forwarded to the IRB. 
The monitor will be available bet ween visits if the Investigato r or other staff needs information. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 55  12.2. Data Collection 
The Investigator will be responsible for maintaining accurate a nd adequate source documents. 
All relevant observations and data related to the study will be  recorded. This will include medical 
and medication history, physical examinations, a review of inclusion and exclus ion criteria, 
investigational treatment admin istration and record of sample c ollection, clinical assessments, 
AEs, and final evaluation(s).  
Data for each participant will be recorded on the eCRF. An eCRF  must be completed for every 
participant enrolled in the st udy. When data are complete, the Investigator or medically qualified 
sub-Investigator listed on FDA Form 1572 will apply his/her sig nature on the eCRF indicating 
he/she has reviewed and approve s of the data collected on the e CRF. The monitor will review all 
eCRFs and compare data to those contained in clinic notes and p articipants’ source 
documents/medical records. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 56  13. QUALITY CONTROL AND QUALITY ASSURANCE 
13.1. Monitoring 
Site personnel will be provide d with training on how to collect  quality data for the study, and a 
Sponsor monitor or designee will be contacting the site periodi cally to review study conduct and 
data recorded at the site. At  the Sponsor’s discretion, on-site monitoring visits may be conducted 
prestudy, during the study, and fo llowing study completion. The se visits are to provide the 
Sponsor with the opportunity to ev aluate study progress; verify  the accuracy and completeness of 
source data and eCRFs; and ensur e that all protocol and Good Cl inical Practice (GCP) 
requirements, applicable country -specific regulations, and Inve stigator obligations are being 
fulfilled. The Sponsor may termina te study participation if study-site personnel do not follow the 
protocol or GCP. Additionally, individual participants may be e xcluded if a medical record 
review indicates protocol devia tions or if other factors appear  to jeopardize the validity of the 
study. 
The Investigator agrees to coopera te with the monitor to ensure that any problems detected 
during the monitoring visits are resolved. 
13.2. Quality Control and Quality Assurance 
The Sponsor may conduct quality a ssurance audits of this study.  If such an audit occurs, the 
Investigator agrees to allow the auditor direct a ccess to all r elevant documents (eg, all participant 
records, medical records, and eCRF s) and access to all correspo nding portions of the office, 
clinic, laboratory, or pharmacy t hat may have been involved wit h the study. The Investigator will 
allocate his or her time and that of the study-site personnel to the auditor to discuss findings and 
any relevant issues. 
In addition, regulatory agencie s may conduct a regulatory inspection of this study. If such an 
inspection occurs, the Investigat or agrees to notify the Sponsor upon notification by the 
regulatory agency. The Investigat or agrees to allow the inspect or direct access to all relevant 
documents and to allocate his or her time and that of the study -site personnel to the inspector to 
discuss findings and any relevant issues. The Investigator will allow Sponsor personnel to be 
present as an observer during a r egulatory inspection, if requested. 
13.3. Laboratory Accreditation 
The laboratory facility used for a nalysis of clinical laborator y samples must provide evidence of 
adequate licensure or accredita tion. Copies of l aboratory certification, licensure, and reference 
ranges (as appropriate) will be  supplied to the Sponsor prior to study initiation. The Sponsor or 
designee should be notified of any changes in reference range values or certification/license renewal during the study. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 57  14. ETHICS 
14.1. Ethical Conduct of the Study 
The Investigator will ensure t hat this study is conducted in fu ll conformity with the current 
revision of the 1964 Declaration of Helsinki. 
The Investigator is generally not to deviate from the protocol.  In medical emergencies, the 
Investigator will use medical j udgment and will remove the part icipant from immediate hazard. 
The Investigator will immediately notify the Sponsor and IRB re garding the nature of the 
emergency and the course of acti on taken. The Investigator is to notify the Sponsor of any 
inadvertent protocol deviati ons upon discovery and is to docume nt the deviations appropriately 
in the study files or  on the eCRFs. The Sponsor assumes no resp onsibility or liability for any 
deviations. Major changes in the protocol ini tiated by the Spon sor will be provided as an 
amendment and must be approved by t he IRB prior to implementati on (refer to Section 14.4). 
14.2. Good Clinical Practice 
The study will be conducted according to the protocol, guidelin es established by the International 
Council for Harmonisation (ICH) f or GCP in clinical studies and  country-specific requirements 
as applicable. 
14.3. Informed Consent 
Each individual will be provided with oral and written informat ion describing the nature, purpose 
and duration of the study, partic ipation/termination conditions , and risks and benefits. Prior to 
initiation of any study-related pro cedures, participants (and/o r their parent or legal guardian for 
participants under 18 years of age) will sign and date the ICF to participate in the study. 
Participants under 18 years of a ge (and their parent or legal g uardian) will review the ICF and 
sign a Child Assent Form, according to local institution/IRB gu idelines. The parent or legal 
guardian for participants under  18 years of age will also sign and date an authorization form 
required under the Health Insuran ce Portability and Accountabil ity Act (HIPAA), if applicable, 
that authorizes the use and disclo sure of the participant’s protected health information. In the 
event of a pregnancy in the fema le partner of a male participant, a pregnancy consent form will 
be provided to allow the f ollow-up of the pregnancy. 
Participants unable to sign the I CF may participate in the stud y if a legal representative or 
witness provides the consent (in accordance with the procedures  of ICH-GCP and local 
regulations) and the participant confirms his/her interest in s tudy participation. The participant, 
parent, or legal guardian will be informed that he/she can free ly withdraw consent and stop 
participation in the study a t any time with no prejudice to further treatment. It is the parent or 
legal guardian’s responsibility  to communicate this decision to  the Investigator. 
14.4. Institutional Review Board and Regulatory Approval 
The Investigator must inform and obtain approval from the IRB f or the conduct of the study at 
named sites and for the protoco l, the participant ICF, and any other written information that will 
be provided to the participants a nd any advertisements that wil l be used. Written approval must 
be obtained prior to enrollment  of participants into the study and shipment of study drug. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 58  Proposed amendments to the proto col and documents must be discu ssed with the Sponsor and 
CRO, and then submitted to the IRB for approval, as well as sub mitted to regulatory authorities 
for approval prior to implement ation. Amendments may be impleme nted only after a copy of the 
local IRB approval letter has been transmitted to the Sponsor. Amendments that are intended to 
eliminate an apparent immediate hazard to participants may be i mplemented prior to receiving 
Sponsor or IRB approval. However , in this case, approval must b e obtained as soon as possible 
after implementation. 
The Investigator will be responsib le for ensuring that an annua l update is sent to the IRB to 
facilitate their con tinuing review of the study (if needed) and  that the IRB is informed about the 
end of the study. Copies of the upda te, subsequent approvals, and final letter must be sent to the 
Sponsor. The Investigator will in form the IRB of any reportable  AEs. 
14.5. Essential Documentation Requirements 
The Sponsor or Sponsor’s representative will collect from the investigational site the required 
essential regulatory documents pe r ICH guidance prior to study drug shipment to the site. 
14.6. Confidentiality 
The Investigator must ensure tha t the participant’s privacy is maintained. In the eCRF and other 
documents submitted to the Sponsor, participants will be identi fied by a participant study number 
only. Documents that are not submitted to the Sponsor (eg, sign ed ICF) should be kept in a 
strictly confidential f ile by the Investigator. 
The Investigator shall permit au thorized representatives of the  Sponsor, regulatory agencies, and 
IRBs to review the portion of the participant’s medical record that is directly related to the study. 
As part of the required content of informed consent, the partic ipant must be informed that his/her 
records will be reviewed in this manner. 
14.7. Regulatory, Ethical, and Legal Obligations 
The study will comply with the applicable local data protection  regulations. Data collected will 
be pseudonymized. 
The processing of the personal data of participants will be min imized by making use of a unique 
participant study number only on study documents and electronic  database(s). 
All study documents will be stored securely and only accessible  by study staff and authorized 
personnel. The study staff will safeguard the privacy of partic ipants’ personal data. 
The participant information sheet/informed consent for the stud y will inform participant of their 
rights. 
14.8. Study Documentation and Data Storage 
The Investigator must retain a c omprehensive and centralized fi ling system of all study-related 
documentation that is suitable for inspection by the Sponsor an d representatives of regulatory 
authorities. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 59  The Investigator must retain e ssential documents as detailed in  Section 15.2. Participant files and 
other source data (including copi es of protocols,  original repo rts of test results , investigational 
agent dispensing logs, correspondence, records of informed cons ent, and other documents 
pertaining to the conduct of the s tudy) must be kept for the maximum period of time permitted 
by the institution. Documents shoul d be stored in such a way that they can be accessed/data 
retrieved at a later date. C onsideration should be given to sec urity and environmental risks. 
No study document will be destroyed without prior written agreement between the Sponsor and 
the Investigator. Should the Inve stigator wish to assign the st udy records to another party or 
move them to another location, w ritten agreement must be obtain ed from the Sponsor. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 60  15. DATA HANDLING AND RECORDKEEPING 
15.1. Inspection of Records 
The Sponsor or Sponsor’s represent atives will be allowed to con duct site visits to the 
investigation facilities for th e purpose of monitoring any aspe ct of the study. The Investigator 
agrees to allow the monitor to i nspect the drug storage area, s tudy drug stocks, drug 
accountability records, participa nt charts and study source doc uments, and other records relative 
to study conduct. 
The Investigator agrees to main tain a regulatory binder, paper or electronic, in a current, 
organized fashion; this binder will contain documentation supportive of the protocol- and 
GCP-compliance of the study. The  contents of the binder will be organized according to the 
standards of ICH E6, Section 8 (Essential Documents). The Inves tigator agrees to make this 
binder accessible to the monitor, auditor, and representatives of regulatory agencies and the IRB. 
15.2. Retention of Records 
The Investigator will maintai n adequate records, including part icipants’ medical records, 
laboratory reports, signed consen t forms, drug accountability r ecords, safety reports, information 
regarding participants who disc ontinued the protocol, and any o ther pertinent data. All study 
records must be retained for at l east 2 years after the last ap proval of a marketing application in 
the US or an ICH region and unt il (1) there are no pending or c ontemplated marketing 
applications in the US or an I CH region, or (2) at least 2 years have elapsed since the formal 
discontinuation of clinical deve lopment of the study drug under  study. The 
Investigator/institution should ret ain participan t identifiers for at least 15 years after the 
completion or discontinuation of s tudy. Study participant files  and other resource data must be 
kept for the maximum period of time permitted by the hospital or institution but not less than 
15 years. These documents should be retained for a longer perio d, if required by the applicable 
regulatory requirements or by the  Sponsor. The Sponsor must be notified should the 
Investigator/institution be unable to continue with the maintenance of study participant files for the full 15 years. All study record s must be stored in a secure and safe facility. 
The Investigator must retain pr otocols, amendments, IRB approva ls, copies of the Form 
FDA 1572, signed and dated consent forms, medical records, eCRF s, drug accountability 
records, all correspondence, a nd any other documents pertaining  to the conduct of the study. 
If the Investigator moves, withdraws from an investigation, or retires, the responsibility for 
maintaining the records may be  transferred to another person who will accept responsibility. 
Notice of transfer must be ma de to and agreed by the Sponsor. T he Investigator must notify the 
Sponsor immediately in the event of accidental loss or destruction of any protocol records. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 61  15.3. Disclosure of Information 
Participants’ medical informati on obtained as a result of this study is considered confidential, 
and disclosure to third parties other than those noted in this protocol is prohibited. Subject to any 
applicable authorization(s), a ll reports and communications rel ating to participan ts in this study 
will identify participants only by initials and number.  
Medical information resulting fro m a participant’s participatio n in this study may be given to the 
participant’s personal physicia n, other authorized parties, or appropriate medical personnel 
responsible for the participant’s  participation in this clinical study. Data generated in this study 
will be available for inspection on request by government regulatory agency auditors; the 
Sponsor, the Sponsor’s Medical M onitor, and their designated re presentatives; the IRB; and 
other authorized parties. All information concerning the study drug and the Sponsor’s operations 
(such as patent applications, for mulas, manufacturing processes , basic scientific data, or other 
information supplied by the Sponsor and not previously publishe d) is considered to be 
confidential and shall remain the sole property of the Sponsor. 
The Investigator agrees to use this information only in conducting this study and not to use it for 
other purposes without the Sponsor’s prior written consent. The  information developed in this 
clinical study will be used by the Sponsor in the clinical deve lopment of GBT021601 and, 
therefore, may be disclosed by the  Sponsor as required to autho rized parties (including its 
corporate partners for the s tudy drug, if any, and their design ated representatives), other clinical 
Investigators, pharmaceutical companies, the US FDA, and other government agencies. 
Any information, inventions, disc overies (wheth er patentable or not), innovations, suggestions, 
ideas, and reports made or develo ped by the Investig ator(s) as a result of conducting this study 
shall be promptly disclosed to t he Sponsor and shall be the sole property of the Sponsor. 
The Investigator agrees, upon the  Sponsor’s request and at the Sponsor’s expense, to execute 
such documents and to take suc h other actions as the Sponsor de ems necessary or appropriate to 
obtain patents in the Sponsor’s  name covering any of the forego ing. 
Global Blood Therapeutics, Inc.  GBT021601-012 
Clinical Study Protocol v6.0, Amendment 5   
CONFIDENTIAL 64  18. REFERENCES 
Badawy SM, Payne AB, Rodeghier MJ, Liem RI. Exercise Capacity and Clinical Outcomes in 
Adults Followed in the Cooperati ve Study for Sickle Cell Diseas e (CSSCD) Eur J Haematol. 
2018 October; 101(4): 532–541.  
Bunn HF. Pathogenesis and treatme nt of sickle cell disease. N E ngl J Med. 1997;337(11):762-769. 
Chonat S, Fields E, Baratz H,  Watt A, Pochron M, Dixon S, et al . Improvement in Red Blood 
Cell Physiology in Children with Sickle Cell Anemia Receiving V oxelotor. Blood. Nov 13, 2019 
(Supp 1); 2281 
FDA Guidance for Industry: Drug -Induced Liver Injury: Premarket ing Clinical Evaluation. 2009. 
Available at: https://www.fda .gov/downloads/guidances/UCM174090.pdf. Accessed 
08 January 2019. FDA Guidance for Industry: Estim ating the Maximum Safe Starting  Dose in Clinical Trials for 
Therapeutics in Adult Healthy Volunteers. 2005. 
Global Blood Therapeutics, Inc . GBT021601 Investigator’s Brochu re. Version 1.0, 2020. 
Howard J, Hemmaway CJ, Telfer P , Layton DM, Porter J, Awogbade M, et al. A phase 1/2 
ascending dose study and open-la bel extension study of voxeloto r in patients with sickle cell 
disease. Blood. 2019;133:1865–1875. 
Hutchaleelaha A, Patel M, Wa shington C, Siu V, Allen A, Oksenberg D, et al. Pharmacokinetics 
and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults an d Patients with Sickle Cell 
Disease, Br J Clin Pharmacol. 2019;1–13. Metcalf B, Chuang C, Dufu K, Pa tel M, Silva-Garcia A, Johnson C, et al. Discovery of GBT440, 
an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemogl obin. ACS Med Chem Lett. 2017 
Jan 23;8(3):321-326. Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, et al. GBT440 increases haemoglobin 
oxygen affinity, reduces sickli ng and prolongs RBC half-life in  a murine model of sickle cell 
disease. Brit J Haematol. 2016;175(1):141–53. 
Otto JM, O'Doherty AF, Hennis PJ, Cooper JA, Grocott MP, Snowdon C, Carlisle JB, Swart M, 
Richards T, Montgomery HE.  Asso ciation between preoperative haemoglobin concentration and 
cardiopulmonary exercise variab les: a multicenter study. Periop er Med (Lond). 2013 Sep 
13;2(1):18.  
Oxbryta
®, United States Full Prescribing Information, 2021 
http://www.oxbryta.com/pdf/prescribing-information.pdf 
United States Food and Drug Adminis tration Guidance for the Ind ustry: Estimating the Maximum 
Safe Starting Dose in Clinical T rials for Therapeutics in Adult Healthy Volunteers. July 2005. 
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 
randomized trial of voxelotor in s ickle cell disease. N Engl J Med. 2019;381:509-519. 
Wright SE, Pearce B, Snowden CP, Anderson H, Wallis JP. Cardiop ulmonary exercise testing 
before and after blood transfusion: a prospective clinical stud y. Br J Anaesth. 2014 
Jul;113(1):91-6. doi: 10.1093/bja/aeu050.  